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The rapid increase in antimicrobial resistance (AMR) has become a major threat to the 
successful management of infectious diseases. To counteract this global threat, development 
of novel treatment strategies is essential. A promising strategy may be exploiting collateral 
sensitivity; a phenomenon that occurs when a microorganism that has developed resistance to 
one antimicrobial agent, exhibits increased susceptibility to another antimicrobial agent. In 
order to develop novel treatment strategies and prevent further resistance development, we 
aimed to explore the generality of the concept of collateral sensitivity in clinical urinary tract 
isolates of E. coli. Furthermore, we wanted to investigate the underlying mechanisms of 
collateral sensitivity. 
Methods 
We evolved resistance to mecillinam in a collection of clinical isolates of E. coli. Ten were 
selected for further determination of possible collateral sensitivity and cross-resistance 
networks. The IC90-assay with micro broth dilution was used for this purpose, which we 
tested for eight different antimicrobial agents. The results were displayed in heat maps and 
graphs showing the distribution of AMR to various agents. PCR and DNA sequencing were 
performed for the mrdA gene to detect mutations that may confer mecillinam resistance. 
Results 
According to our results both collateral sensitivity and cross-resistance occurred in 
mecillinam resistant isolates. Chloramphenicol presented the highest tendency of collateral 
sensitivity, while ciprofloxacin presented the highest tendency of cross-resistance. In general, 
a substantial tendency for collateral sensitivity frequently appeared compared to cross-
resistance. Moreover, 13 synonymous point mutations were observed in the mrdA gene, 
leading to no alteration in the amino acid sequence. 
Conclusion 
Based on our in vitro results, we suggest mecillinam could be a good candidate to be 
employed as the first drug of choice for UTIs caused by E. coli. Mecillinam resistant isolates 
exhibited a clear tendency for collateral sensitivity, which we believe would occur on the 
population level as well. Further investigations of the underlying mechanisms of collateral 
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Antimicrobial resistance (AMR): “resistance of a microorganism to an antimicrobial drug 
that was originally effective for treatment of infections caused by it” (1). 
Cross-resistance (CR): occurs due to a single resistance mechanism which confer resistance 
to an entire class of antimicrobial agents (2).  
Collateral sensitivity (CS): in the context of microbiology, CS occurs when a microorganism 
that has developed resistance to one antimicrobial agent exhibits increased susceptibility to 
another antimicrobial agent (3).  
Community-acquired infection: infections are acquired in the community, in contrast of 
hospital-acquired infections (4). 
Hospital-acquired infections: infections are acquired in hospitals and other healthcare 
facilities, in contrast of community-acquired infections. The patient in this case must have 
been admitted for reasons other than infection, and has shown no signs of active or incubating 
infection (4).  
In vitro: “in glass”, studies are performed with microorganisms, cells or biological molecules 
outside their normal biological context (5). 
In vivo: “in the living”, studies are performed in living organisms (5). 
Isolate: a population of bacterial cells in pure culture derived from a single colony. In the 
context of clinical microbiology, isolates are usually derived from the primary culture of a 
clinical specimen obtained from an individual patient (6).  
Multidrug-resistance (MDR): defined as acquired non-susceptibility to at least one 
antimicrobial drug in three or more antimicrobials categories (2).  
Nucleotides: building blocks of nucleic acids in DNA and RNA. Nucleotides have three 
characteristics components; a nitrogenous base (purine or pyrimidine), a pentose and a 
phosphate (5). 
Nucleic acids: biomolecules essential for all known form of life. Nucleic acids, which include 




Pathogen: a bacterium, virus or other microorganism that can invade the human body and 
cause disease (7).  
Plasmid: an “extrachromosomal”, circular DNA in the bacterial cells that replicates 
independently of the chromosome and regulate its own replication (8).  
Species: the basic category of bacteria; a named group of bacteria which shows a high degree 
of overall similarity as compared to other, more vaguely related strains. Currently there are no 
universally accepted species definitions (6). 
Strain: the descendants of a single isolation in pure culture, usually derived from a single 
initial colony. It may be considered as an isolate or a group of isolates that can be 
distinguished from other isolates of the same genus and species by phenotypic or genotypic 
characteristics. E.g. Two isolates can be representatives of one strain, however two strains can 
never be the same isolate (6). 
Transposon: “jumping gene”, a DNA sequence that can move from one place in the DNA to 










The phrase “survival of the fittest” originated from an evolutionary theory that describes the 
mechanism of natural selection (9). As early as in the 1850s, Charles Darwin discovered the 
foundation of a scientific theory on adaptation of animals and plants and their incredible 
biodiversity. Few would expect that this would give rise to human’s biggest public health 
threat in the 21st century; antimicrobial resistance, a global threat driven by the evolution of 
resistant microorganisms. To combat this threat, novel infectious treatment strategies are 
essential. A promising strategy may be exploiting collateral sensitivity; a phenomenon 
brought to light in 1952, which for the past few years has caught the interest of researchers 
again. Translating collateral sensitivity networks into treatment-guidelines may retard the 




1.2 Antimicrobial agents 
The discovery of penicillin by Alexander Fleming in 1928 is considered the beginning of the 
history of modern medicine, as well as one of the greatest discoveries of the 20th century. An 
antimicrobial agent is a substance that either kills or inhibits the growth of microorganisms 
(4). These agents are categorized according to the microorganisms they act primarily against. 
Antibacterial agents are used to treat bacterial infections, antifungal drugs act against fungi, 
antiviral drugs are used specifically for treating viral infections, and antiprotozoal drugs act 
against protozoa (4). In this thesis antimicrobial agents or antimicrobials refer to antibacterial 
drugs. 
 
1.2.1 Classification of antimicrobial agents 
Antimicrobial agents are derived naturally from microorganisms, chemically modified or 





Ø spectrum of activity; either broad- or narrow-spectrum 
Ø effect on bacteria; antimicrobials can either kills the microorganisms (bactericidal) or 
inhibits their growth (bacteriostatic). This distinction is rather blurred since some of 
the drugs have bactericidal effect on some species, but have bacteriostatic on others 
Ø and mode of action (4). 
I have chosen to describe antimicrobials agents in the context of their mode of action, which 
categorize them into five categories based on their site of activity (4): 
i) Inhibition of cell wall synthesis 
The bacterial cell wall is essential for maintenance of the integrity of bacterial cells (4).  The 
cell synthesis is hence an important target for antimicrobial agents. A unique and main 
component of the bacterial cell wall is peptidoglycan, which is a mixed polymer of hexose 
sugars and amino acids (4). In Gram-positive bacteria, peptidoglycan forms a thick layer 
external to the cell membrane, and may contain other macromolecules (4). While in Gram-
negative bacteria, the peptidoglycan layer is thin and is also overlaid by an outer membrane 
with other components such as lipoproteins and lipopolysaccharides (4). β-lactams target the 
bacterial cell wall synthesis by specific covalent binding to penicillin-binding proteins 
(PBPs), such as mecillinam and PBP 2 (10). The mode of action for mecillinam differs from 
other β-lactams, which bind to other PBPs (10). PBP 2 is responsible for the elongation of 
rod-shaped cells and generates the mature peptidoglycan molecules. Thus cells treated with 
mecillinam will have impaired formation of cross-links and become enlarged, non-dividing 
spheres that ultimately lyse (11, 12).  
ii) Inhibition of nucleic acid synthesis 
DNA and RNA are the keys to replication of all living forms. Antimicrobials, such as 
quinolones (e.g. ciprofloxacin), disrupt DNA or RNA synthesis by interfering with either 
nucleotide or nucleic acid biosynthetic processes in the cell (4). This causes interference of 
normal cellular processes, for instance bacterial transcription or replication, and thus cell 
viability as well (4).  
iii) Inhibition of protein synthesis 
Enzymes and most of cellular structures are primarily made of proteins, which are essential 




target bacterial protein synthesis by binding to either the 30S or 50S subunits of the ribosomes 
(the site of protein synthesis). Consequently, this will lead to cell death of the organism or 
inhibition of its cell growth or replication (4). Antimicrobial classes that have this mode of 
action are for instance aminoglycosides (e.g. gentamicin), macrolides, tetracyclines and 
miscellaneous (e.g. chloramphenicol and nitrofurantoin) (4). 
iv) Inhibitor of cell membrane functions 
Disruptions or damage to the cell wall structure may result in the loss of important solutes 
essential for survival of the cell (4). Unfortunately both eukaryotic and prokaryotic cells have 
this cell wall structure and consequently some of the antimicrobials in this class may often be 
lead to severe adverse effects for systemic use in humans (4). Therefore most clinical use is 
restricted to topical applications, such as polymyxin B. 
v) Inhibition of other metabolic pathways 
Inhibition of other metabolic pathways includes the folic acid pathway, a process which is 
needed for production of precursors for nucleic acid synthesis (4). For instance trimethoprim 
acts by preventing tetrahydrofolic acid synthesis. This is required for the synthesis of different 
nucleotides in the DNA and RNA (4). 
 
 
1.3 Antimicrobial resistance 
The successful discovery of antimicrobial agents was unfortunately compromised by the 
inevitable emergence of antimicrobial resistance (AMR) from the time they were first used 
(1). As the quote “Some men are born great, some achieve greatness, and some have 
greatness thrust upon them” by William Shakespeare, some bacteria are born resistant, others 
have resistant thrust upon them. In other words, enhanced levels of resistance can be achieved 
by mutations in the bacterial genome (de novo) or by acquisition of resistance-conferring 
genes through horizontal gene transfer (HGT) (4). This will be described in more detail in the 
section on AMR mechanism (section 1.3.4). I will first address the true cost of AMR, the 
current status in Europe and give a brief introduction to possible novel strategies to deal with 
the issue of AMR development both from the scientific/medical communities as well as the 




1.3.1 The true cost of AMR 
In the last 70 years, there has been a continual race between the discovery and development of 
novel antimicrobials and the bacteria that will respond to the selective pressure and novel 
AMR mechanisms that are developed and selected for (4, 13). 
At the present time, AMR is listed as one of the greatest threats to human health according to 
recent World Economic Forum Global Risks reports (14). It is also recognized as a growing 
global threat to the successful management of infectious diseases (15), with over 2 million 
AMR infections per year in the US alone (16). According to WHO, deaths caused by 
infectious diseases represent more than half of disease-related deaths globally (17). The 
emergence of bacteria with a diversity of resistance mechanisms has intensified the challenges 
associated with infection control and treatment strategies. 
 
1.3.2 Current status and possible strategies for improvement of treatment 
strategies 
Though AMR occurs naturally, over- and misuse of antimicrobial agents accelerates this 
process (18, 19). According to the annual surveillance reports by the European Centre for 
Disease Prevention and Control (ECDC), there is an association between the consumption 
levels of antimicrobials and the levels of AMR (20, 21). Figure 1 gives an overview of the 
consumption of antimicrobials for the majority of European countries in 2014 (20). Greece, 
Romania and France were the three countries with the highest consumption of antimicrobial 
agents. Another report of ECDC from the same year gave the latest data on AMR for different 
bacterial species in Europe (21). For invasive isolates of E. coli with resistance to third-
generation cephalosporins in 2014, there is a clear correlation of resistance prevalence and 
antimicrobial agents consumption (Figure 2). Bulgaria, Cyprus, Italy, Romania and Slovakia 
were countries with highest resistance prevalence in 2014, in which the percentage of 





Figure 1: Consumption of antimicrobials for systemic use in the community for different European countries 2014. 






Figure 2: Percentage of invasive isolates of E. coli with combined resistance to third-generation cephalosporins in 
2014. Permission obtained from: (21, 22). 
 
Microorganisms develop defensive mechanisms, which protect them from antimicrobials and 
allow them to become less sensitive (4). Switching to another antimicrobial or higher dosage 
is not always sufficient. In the latter, increased dosage is associated with greater adverse 
effects and toxicity for the patient. Moreover, use of high doses of antimicrobials has the 
potential to promote increase of cross-resistance in clinical settings (23). 
So why do we not develop novel antimicrobials that can combat resistant bacteria? In order to 
do this, the developed antimicrobials must be effective against resistant microorganisms (e.g. 
those with novel antimicrobial mechanism(s)), which is a tremendously challenging and time-
consuming task (24). The dramatic decrease in novel antimicrobial agents approved is not 
only due to scientific but also other several factors, including commercial ones. 
Pharmaceutical companies consider development of antimicrobial agents a poor economic 




treating high blood pressure (hypertension) that are taken daily for the rest of a patient’s life 
while antimicrobials are taken only for a short period of time. This is one of the major reasons 
why companies have stopped developing antimicrobial agents. In addition to the mentioned 
factors, use of a novel antimicrobial agent will probably eventually lead to development of 
AMR as well. Hence changing our antimicrobial treatment strategies may be a better solution.  
One approach to counteract drug resistance development in bacteria is combination therapy 
where two or more drugs are administered simultaneously. The first case showing success 
with combination therapy was in 1940s, based on a so-called synergistic effect (25). Synergy 
is the interaction of drugs where the combined effect is greater than the sum of drugs 
individually. Combination therapy has been considered a promising drug therapy strategy to 
the rising health threat of AMR until associated severe adverse effects were observed for 
some combination therapies. For instance the combination of tobramycin and piperacillin has 
shown renal toxicity, skin rash and ototoxicity (26). Furthermore, several studies have shown 
no difference in clinical outcomes between combination therapy and monotherapy (26). 
However, a more favorable strategy may be alternating therapy, also known as collateral 
sensitivity cycling. Translating collateral sensitivity networks into treatment-guidelines may 
retard the evolution of antimicrobial resistance by constraining the evolutionary paths towards 
resistance (27). This will be described in more detail in the section 1.4. To approach solutions 
for AMR we need to understand how currently used antimicrobial agents work and how 
bacteria are able to survive treatment with these antimicrobials. 
 
1.3.3 WHO global action plan to tackle AMR 
Several antimicrobial stewardship programs have developed strategies to control the 
emergence of AMR. In May 2015, The World Health Assembly of WHO endorsed a global 
action plan to tackle AMR (28). Their goal is to ensure continuity of successful treatment and 
prevention of infectious diseases with effective and safe medicines, used in a responsible way, 
and accessible to all who need them. They set out five strategic objectives to achieve this 
goal: 
1) “to improve awareness and understanding of AMR”; this can promote behavioral 




2) “to strengthen knowledge through surveillance and research”; integrated programs 
are needed for surveillance of AMR in all countries, which aim to extend reduction in 
prevalence of AMR by using the collected data. This should be supported by national 
governments, professional organizations and industries through the generation of such 
knowledge and bringing it into practice. 
3) “to reduce the incidence of infection”; this can be achieved through better hygiene 
and infection prevention (e.g. better sanitation, hand washing, food and water safety), 
vaccine programs and sustainable husbandry practices. 
4) “to optimize the use of antimicrobial agents”; there is need for effective, rapid, low-
cost diagnostic tools for guidance on the optimal use of antimicrobials. It is also 
important to improve regulations of the purchase and compliance of patient and health 
care provider. 
5) “develop the economic case for sustainable investment that takes account of the needs 
of all countries, and increase investment in new medicines, diagnostic tools, vaccines 
and other interventions.”; studies on the economic cost of AMR should be 
implemented for all countries, not only limited to developed countries. Additionally 
there is need for affordable tools to inform health personnel of the susceptibility of the 
pathogens to available antimicrobials (28). 
 
1.3.4 Development and dissemination of antimicrobial resistance 
Some bacteria are naturally resistant to specific antimicrobials (intrinsic resistance). Intrinsic 
resistance is the inherent ability of a species to resist the mode of action(s) of a certain 
antimicrobial agent through its inherent structural or functional characteristics (4). The 
mechanisms of this could be the lack of drug target. While acquired resistance occurs when 
a particular species, initially susceptible to a certain antimicrobial, obtains the ability to resist 
the mode of action(s) to the respective antimicrobial agent (4). 
This thesis only deal with acquired resistance mechanisms. Definitions and examples of such 
resistance mechanisms will be described in section 1.3.4.2. But first, I will address how 





1.3.4.1 Emergence of genes conferring resistance 
A mutation is a permanent alteration in the sequence of nucleotides in a DNA molecule. 
When there are changes in the DNA sequence it can lead to genetic variation and affect the 
phenotype (8). However, a DNA mutation may or may not affect the phenotype of the 
organism depending on if the mutation leads to alteration in the amino acid sequence (29). A 
mutation can be classified by the type of alteration in the DNA, the alteration it causes in the 
protein, or by whether the mutation is a spontaneous change in the genetic material or induced 
by a mutagen in the environmet (e.g. plasmids or transposons) (29). The different types of 
mutation are:  
• Point mutation: a nucleotide in one chromosomal position is substituted of another 
nucleotide. This usually takes place during DNA replication. There are different types 
of point mutations;  
i) Transition: substitution of a nitrogenous base, such as a purine base (A or G) 
with another purine, or a substitution of a pyrimidine (T or C) with another 
pyrimidine (29).  
ii) Transversion: substitution of a purine with a pyrimidine or vice versa. This is 
the most common type of mutation, which may or may not alter the functional 
properties and stability of the protein (4). 
iii) The formation of a STOP codon in the nucleotide sequence: causing premature 
termination of a certain protein, which almost always inactivates the protein 
(8). 
• Deletion or addition of a nucleotide: occurs during DNA replication. This may be 
induced by mobile elements such as transposons (29). 
When mutations in the nucleotides do not lead to alteration in the amino acid sequence (the 
protein), they are called synonymous mutations (30). This is because the mutated codon still 
encodes for the same amino acid as the original codon. Whereas mutations that may change 
the protein sequence are called non-synonymous mutations (30).  
Mutations in the DNA may also arise through inversion (flipping a region so that it lies in 
reverse orientation), deletion (a number of base pairs have been removed) or insertion 
(incorporation of another DNA sequence) (8). An insertion or a deletion of nucleotides other 




leads to a change in the protein amino acid sequence, which can lead to alteration in the 
protein function, reduction of activity or inactivation the protein.  
 
1.3.4.2 Vertical and horizontal gene transfer 
AMR mechanisms can be transferred vertically. This is transmission of genes conferring 
resistance from the bacteria to its daughter cells during DNA replication and cell division 
(13).  
Development of AMR can occur through mutations (as mentioned above) and also through 
acquisition of new AMR genes by HGT. HGT occurs when the genetic material is contained 
in mobile genetic elements, such as plasmids, transposons and bacteriophages, and transferred 
between the same or different species (13). HGT is primarily mediated by conjugation, 
transduction or transformation (4, 8); 
1. Conjugation: occurs when the donor cell transfers DNA to the recipient cell by direct 
contact through a pilus. The genetic material is exchanged between bacterial cells, 
whereas this process involves transfer of mobile genetic elements such as plasmids or 
transposons (4, 8).  
2. Transduction: gene transfer through transduction involves bacteriophage, a virus that 
infects and replicates within a bacterium. When the bacteriophage infects the recipient 
cell, it will at the same time donate its own DNA into it. Thus if the DNA of the 
bacteriophage contains resistant genes, which has been incorporated with its own 
DNA when being replicated inside a resistant bacterium, the resistant gene will be 
transferred to other cells (4, 8). 
3. Transformation: occurs when a bacterium lyses, leading to release of free 
extracellular DNA, often in the form of plasmid. This may be taken up by the recipient 
bacterial cell, which will incorporate it into its genome. Hence lysis of a resistant cell 
will cause release of resistant genes that may be taken up by other recipient cells (4, 
8). 
Mutations are clearly important with respect to resistance development. However, the main 
problem in spread of AMR is the mobile genetic elements that harbor resistance determinants 
(4). This occurs often for the antimicrobial agents of last resort, e.g. vancomycin and 




only rare chromosomal mutation resistance was described. Nonetheless, a recent study reports 
the emergence of colistin resistance on a plasmid (33). 
 
1.3.5 Fitness cost of AMR 
AMR is caused by the development of different antimicrobial resistance mechanisms (section 
1.3.4). Newly acquired resistance is (often) costly and reversal of resistance in drug-free 
environments occurs mainly as a function of these costs. As an example, several studies have 
shown that antimicrobial resistant isolates may have slower growth rates than susceptible 
isolates (34, 35), hence AMR can lead to harmful adverse effects for the bacteria. This is 
referred to as the “cost” of resistance (36).  
In principle, antimicrobial sensitivity may be renewed by temporarily exclusion the 
antimicrobials for which resistance has emerged, thus allowing competitive replacement of 
resistant bacteria with sensitivity ones that have higher fitness (36). However, this 
disadvantage can be ameliorated by compensatory evolution through for example, mutations 
that increase or restore the fitness of the resistant isolates (37). This allows resistance to 
persist even without the presence of antimicrobials (32). 
Conventional antimicrobial cycling is based on the assumption that resistance is accompanied 
by a biological fitness cost. In the absence of selective pressure imposed by drug treatment, 
the resistance frequency of a population with high fitness cost is expected to be outcompeted 
by their non-resistant parental WTs and disappear from the bacterial population (32). 
However, due to the uncanny ability to bacteria to adapt, renewing sensitivity is difficult 
because of natural selection and the evolutionary adaption of the resistant bacteria (32). 
Furthermore, the reversal is expected to be slow even if a fitness cost is present (32). 
 
 
1.4 Collateral sensitivity 
As mentioned earlier, a possible favorable strategy to combat AMR is to constrain the 
mutational paths towards resistance taking advantage of the phenomenon of collateral 




resistance to one antimicrobial agent become more susceptible to others (3, 38). Szybalski and 
Bryson used this term for the first time in 1952 when they did research on cross-resistance 
(3). However, it never got much attention until recently. Although there have been several 
studies on this phenomenon, the underlying mechanisms of collateral sensitivity still remain 
unclear.  
In 2013, Imamovic and Sommer suggested that collateral sensitivity cycling could contribute 
to the sustainable use of antimicrobial agents in the clinic for controlling resistant bacteria 
(38). They approached this hypothesis by evolving parallel lineages of E. coli resistant to 23 
antimicrobial agents. These resistant isolates were derived from a laboratory strain (MG1655) 
and two clinical isolates of E. coli. Collateral susceptibility profiles for the different isolates 
were determined by using microtiter plates and 2-fold dilutions of the tested antimicrobial.  
The theory behind Imamovic and Sommer’s suggestions is displayed in Figure 3, and can 
briefly be explained as follows: a pathogenic wild type (WT) cell population (black circles) 
being treated with drug A (blue arrow) at time t0. Over time emergence of resistance for drug 
A will arise (blue circles) and drug A becomes ineffective (t1). By switching to drug B (red 
arrow), which drug A-resistant isolates have become collaterally sensitive to (t2), leading to 
susceptibility of drug A-resistant isolates and selection for cells with WT resistance levels. 
Eventually, resistance to drug B (red circles) will arise (t3) and treatment will get switched 
back to drug A to, which drug B-resistant isolates have become collateral sensitive, resulting 
in susceptibility of drug B-resistant isolates (t0). Therefore through rational cycling between 
drugs A and B, they are counter selecting for resistance thus the emergence of antimicrobial 
resistant populations can be prevented.  
 
Figure 3: Collateral sensitivity cycling. A general model demonstrating the principle of collateral sensitivity cycling, 
showing the eradication of resistant strain when antimicrobials with reciprocal collateral sensitivity profiles (Drug A and B) 





Imamovic et al. also conducted an experiment to provide proof of a principle for collateral 
sensitivity cycling. According to their heat map, showing antimicrobial susceptibility profiles 
of drug-resistant strains relative to the WT, gentamicin (GEN) exhibited collateral sensitivity 
for cefuroxime (CFX). Hence a population of E. coli WT was evolved to become resistant 
toward gentamicin. Once that was achieved, gentamicin-resistant cells were mixed with WT 
cells, and the mixed population was exposed to cefuroxime. This treatment led to complete 
killing of the gentamicin-resistant cells. The same was done with the remaining WT cells, but 
this time they evolved resistance to cefuroxime. Again, cefuroxime-resistant cells were mixed 
with WT cells and exposed to gentamicin. This resulted in complete killing of cefuroxime-
resistant cells and survival of WT cells. Here they demonstrated how collateral cycling could 
be applied to select against resistance (38). 
In recent years, several studies have aimed to extend the knowledge of this phenomenon (27, 
39-44). As mentioned earlier, the underlying mechanisms of collateral sensitivity still remain 
unclear. Many studies offer an insight into this; one among them involved reduction in the 
activity of efflux pumps (39, 43). This is the best-described mechanism, which was first 
explained by Lázár et al. (39). In this work they also performed evolutionary experiments to 
study networks of collateral sensitivity interactions. Three main patterns emerged from their 
susceptibility map; first, collateral sensitivity interactions occurred frequently. Second, the 
mode of antimicrobial action has a strong influence on the distribution of interactions. And 
third, the majority of the collateral sensitivity interactions involved aminoglycosides. 
Lázár et al. suggested that resistance to aminoglycosides, caused the reduction in activity of 
efflux pumps, which altered the susceptibilities to multiple different antimicrobials such as 
ampicillin, fosfomycin and nitrofurantoin (39). The theory was that uptake of 
aminoglycosides is affected by changes in the cell membrane potential, and resistance to this 
antimicrobial group was caused by a reduction in the membrane potential. Simultaneously, 
efflux pumps that use the proton motive force had reduced function because of the reduced 
membrane potential. This leads to increase intracellular accumulation of several other 
antimicrobials whose efflux was dependent on these pumps. This theory was supported 
through whole-genome sequencing (WGS). It revealed that following adaption to 
aminoglycosides, mutations that most likely diminish the function of efflux pumps are 




This so-called trade-off, where the organism is losing one quality or aspect of something in 
return for gaining another quality or aspect, is an important factor of collateral sensitivity 
(27). In the Lázár-study, bacterial trade-off gives rise to alteration of the cell membrane 
permeability, that may not only cause decreased intracellular accumulation of one 
antimicrobial, but also increased intracellular accumulation of others (27, 39). 
Earlier studies on collateral susceptibility frequently used Escherichia coli (E. coli) as the 
prokaryotic model organism (38, 39, 43). It is an advantageous model organism due to its 
rapid growth, the vast knowledge humans have about this bacterium and the diversity of 
molecular tools available. Additionally, it is a very relevant pathogenic bacterium, which will 




1.5 Escherichia coli 
 E. coli is a rod-shaped, Gram-negative bacterium, which is motile and can be with or without 
a capsule (4). E. coli is also non-fastidous and bile-tolerant facultative anaerobe (4). 
This bacterium causes urinary tract infections (UTIs), diarrheal diseases, neonatal meningitis 
and bloodstream infections (septicemia) (4). However, harmless types of E. coli normally 
inhabit the gut of humans and animals, and may also colonize the lower end of the urethra and 
vagina (4). It is when E. coli spreads to other locations outside the intestinal tract, by contact 
and ingestion (faecal-oral route), that it primarily becomes a pathogen (4, 45). This may be 
food-associated or endogenous. The bacterium possesses different antigens, which can be 
used for diagnostics to characterize strains by serotyping (4). 
 
1.5.1 Pathogenic categorization 
E. coli is a diverse group of bacteria and some E. coli strains are more pathogenic than others 
(4). This is due to the carriage of different virulence factors, and makes it suitable to 




- Enteropathogenic E. coli (EPEC): causes sporadic cases and outbreaks of infection 
in babies and young children. The virulence factors they possess are bundle-forming 
pili, intimin and an associated protein (4). 
- Enterotoxigenic E. coli (ETEC): the most important bacterial cause of diarrhea in 
children. The virulence factors they possess are colonization factors and production of 
enterotoxins (4). 
- Entereohaemorrhagic E. coli (EHEC): sporadic cases and outbreaks worldwide, 
which food and unpasteurized milk are important for cause of infection spread. Their 
production of verotoxins affects tissue cultures resulting in diarrhea (4). 
- Enteroinvasive E. coli (EIEC): the most common bacteria for diarrhea in areas of 
poor hygiene. By using plasmid-mediated genes they invade the cells by endocytosis 
(4). 
- Enteroaggregative E. coli (EAEC): causes diarrhea in children in areas where 
resources are poor. They also have characteristic attachment to tissue culture cells. 
Their virulence factors are plasmid-mediated fimbrae and heat-labile toxins (4). 
- Diffuse-aggregative E. coli (DAEC): causing diarrhea in children as well but is 
somewhat controversial. They produce an alpha haemolysin and cytotoxic necrotizing 
factor 1 (4). 
 
Among the diseases mentioned above, UTIs are one of the most common infections in the 
world, which this project will be focusing on (10, 46). 
 
1.5.2 E. coli – clinical relevance 
The current spread of Gram-negative bacteria is a therapeutic challenge. In this project the 
focus will be on E. coli, the most frequently isolated etiological agent from a range of 
infections such as UTIs and septicemia worldwide (4). Beside UTIs being among the most 
common infections seen in the community (10), they are also associated with prominent 
morbidity (4). The annual number of uncomplicated UTIs cases is 130-175 millions 
worldwide, which usually are caused by E. coli (46). Septicemia, originating in the urinary 
tract, is a common and serious complication of UTIs. To reduce mortality of this illness, 
appropriate treatment is critical. However the increasing prevalence of AMR E. coli limits 
clinical options and delays suitable therapy (46). Furthermore, E. coli isolates producing 




(specifically β-lactams) through hydrolysis, are becoming more prevalent in the community 
(10, 47). Carbapenems have been regarded as the drugs of choice to combat multi-resistant 
ESBL-producers (4). However, the emergence of resistant bacterial species to carbapenems 
have been reported and is highly associated with numerous healthcare-related risk factors and 
with high mortality (48). Thus efficient infection-control practices for containment of 
outbreaks and novel treatment strategies are necessary against the emergence of antimicrobial 
resistance in E. coli. 
 
 
1.6 Urinary tract infections 
The urinary tract includes the kidneys, the ureters (the tubes that carry urine from the kidneys 
to the bladder), the bladder (which stores urine) and the urethra (the tube that carries the urine 
from the bladder to the outside) (49). 
UTIs occur when bacteria are introduced into the urethra and move up into the bladder. E. coli 
is the most common organism causing UTIs (4). If the infection remains only in the bladder, 
the infection is called “cystitis”, however if infection travels up past the bladder and into the 
kidneys, it is called “pyelonephritis” (4). 
Cystitis is the most common bacterial infection and causes symptoms such as burning during 
urination and the need to urinate frequently (7). Pyelonephritis is less common than cystitis 
and they have similar symptoms (7). However, pyelonephritis may also cause fever, back pain 
and nausea or vomiting (7). Both infections are more common in women than men due to 
anatomical reasons. Women usually have uncomplicated cystitis and are easily treated with a 
short course of antimicrobial treatment (50). In men, cystitis may also affect the prostate 
gland and therefore is more complicated so treatment for a longer period is necessary (51).  
UTIs may be community- or hospital-acquired (4). There are a variety of mechanical factors 
that can predispose someone to develop a UTI, such as disruption of normal urine flow, 
incomplete emptying of the bladder or factors that facilitate access of organisms to the 





1.6.1 Treatment of UTIs 
According to the Norwegian guidelines from the directorate of Health (“Helsedirektoratet”), 
the antimicrobials recommended for treatment of acute uncomplicated and complicated 
cystitis are trimethoprim, nitrofurantoin and pivmecillinam. The duration of treatment 
depends on whether it is an uncomplicated or complicated infection, 1-3 or 5-7 days, 
respectively (52). 
Treatment guidelines for other part of the world vary in their recommendations compared to 
Norway. For instance, in the United Kingdom (UK), for children of 3 months or older with 
cystitis or lower UTIs, the drugs of choice for treatment are trimethoprim, nitrofurantoin, 
cephalosporins, or amoxicillin (53). First-line agents for symptomatic lower UTIs for non-
pregnant women are trimethoprim or nitrofurantoin in Scotland (54). And according to the 
Infectious Diseases Society of America (IDSA), trimethoprim-sulfamethoxazole is one of the 
traditional first-line drugs in the US (55). With a focus on the situation in Norway and based 
on previous results from the Microbial Pharmacology and Population Biology Research group 
(MicroPop) at UiT – The Arctic University of Norway (Tromsø), which will be described 




Mecillinam is a β-lactam antimicrobial, which was discovered in the 1970s with bactericidal 
effect. Mecillinam, unique among β-lactams, binds selectively to PBP 2 in the Gram-negative 
cell wall, especially E. coli (10). E. coli replicate through binary fission. This is a process 
where cells increase in length and split in two by constricting at the middle of the cell leading 
to synthesis of new cell poles (Figure 4) (56). Directed by a so-called Z-ring, which functions 
as a scaffold for other proteins to attach (such as FtzQ, -A and -Z), the formation of a septum 





Figure 4: A model of cell division including various cell division proteins. 
 
Mecillinam affects the bacterial cell wall by binding to PBP 2 and inhibits the transpeptidase 
activity of the enzyme. PBP 2 is responsible for the elongation of rod-shaped cells. Thus cells 
treated with mecillinam become enlarged, non-dividing spheres that leads to lysis (12). 
Pivmecillinam, which is the prodrug of mecillinam, is a synthetic penicillin for oral use (10) 
(Figure 5). According to the Norwegian guidelines, pivmecillinam dosage is usually 200 mg 3 
times daily for treatment of uncomplicated UTIs (52). In contrast of mecillinam, 
pivmecillinam absorbs readily from the gastrointestinal tract and undergoes enzymatic 
hydrolysis by esterases that liberate the active mecillinam (10).  
 
 





Mecillinam has high clinical efficacy for the treatment of UTIs, and is also well tolerated with 
a low side-effect profile (10, 57). However, MDR bacteria that are resistant to mecillinam 
have been observed and are threatening the treatment of UTIs (58, 59). According to the 
NORM/NORM-VET report, the prevalence of mecillinam resistance has slowly increased in 
UTIs, from 4,2% in 2012, to 5,0% in 2013 and to 6,0% in 2014 (58). Another study that 
aimed to provide an update of antimicrobial resistance in E. coli causing uncomplicated UTIs, 
also showed similar results (59). This update for 2014 in Spain presented a prominent 
increase in resistance, including to mecillinam (1% to 6,5%) (59).  
In the current project, mecillinam was the drug of choice for our focus in making resistant 
mutants. This choice is based on the previous results from MicroPop. In their work, they 
evolved clinical E. coli isolates (isolates from the same ECO-SENS collection as in our study) 
resistant to four different antimicrobial agents, ciprofloxacin, mecillinam, nitrofurantoin and 
trimethoprim. For each isolate they performed MIC testing to determine the susceptibility 
profiles for 16 antimicrobial agents. They generated an overview of distribution of collateral 
sensitivity and cross-resistance as displayed in Figure 6. Based on the results from MicroPop, 




Figure 6: AMR to different antimicrobial agents in various collateral sensitive/cross-resistance phenotypes. The 
average log MIC changes for each AMR group to 16 antimicrobial are compared. Blue coloring indicates collateral 
sensitivity, and red coloring indicates cross-resistance. Permission obtained from: MicroPop research group at UiT – The 




1.7.1 Use of and prevalence of resistance to mecillinam in Norway 
Mecillinam is one of the first line drugs of choice for uncomplicated UTIs treatment in 
Norway (52). According to the NORM/NORM-VET report from 2014, pencillins with 
extended spectrum constitute 41% of penicillins used in Norway (58). This is an increase in 
use compared to 30% in 2003, which is due to increased use of amoxicillin and pivmecillinam 
(58). Pivmecillinam is being used more for UTIs, replacing the role of sulfonamides and 
trimethoprim. Also, the same report shows sales of single antimicrobials, where 
pivmecillinam is one of the antimicrobials that are most frequently used for outpatients. 
Together with phenoxymethylpenicillin and doxycycline, these three represent 47% of all 
prescriptions for outpatients given from primary care when methenamine is excluded.   
As mentioned above, the prevalence of resistance has slowly increased for mceillinam (58). 
However, the report also shows that the susceptibility test results are difficult to reproduce for 
this antimicrobial and therefore, the observed differences may not reflect real changes in 
prevalence. Even though resistance rates among urinary tract isolates have remained relatively 
stable over the last decade, it is trending upwards for most antimicrobials and mecillinam is 
unfortunately one of them (Figure 7). 
 
 
Figure 7: Prevalence of resistance to different antimicrobials in E. coli urinary tract isolates from 2000-2014. 





1.7.2 Use of and resistance prevalence of mecillinam in the world 
Although mecillinam is the most used agent for UTIs in Northern countries (60), the drug is 
not available everywhere (e.g. it is not used in Canada and the US) (57), or not a drug of 
choice in the recommendations of UTIs treatment (54, 55). According to IDSA, trimethoprim-
sulfamethoxazole is the major first-line agent in the US (55). Studies have shown high 
susceptibility rates to mecillinam in Europe and in some countries in the Americas (61, 62). 
For instance according to a surveillance study from 2008 the susceptibility rate of E. coli to 
mecillinam was above 90% for all countries that were included (9 European countries and 
Brazil) (61). This was the second highest susceptibility rate with 95,8% for all countries in 
total, right after fosfomycin with 98,1%. Similar results were reported by Kahlmeter and his 
research group, which the mean level of resistance was less than 2% for all 5 countries 
(Austria, Greece, Portugal, Sweden and the UK) (62). These countries were selected to 
represent different geographical areas in Europe.  
The vast use of mecillinam in northern Europe raises the question if there are any reasons for 
the low prevalence of resistance to mecillinam? This will be addressed on the next section on 
mecillinam resistance mechanisms. 
 
1.7.3 AMR mechanisms to mecillinam in E. coli 
There are different AMR mechanisms to mecillinam. Resistance may occur due to four major 
mechanisms: 
i) antimicrobial inactivation/modification (63, 64) 
ii) alteration in the cell wall composition (e.g. liposaccharide, PBPs) (65-69) 
iii) reduced expression of cell wall porins or 
iv) over-expression of efflux pumps. 
Antimicrobial inactivation/modification may be caused by the production of β-lactamases 
(70). β-lactamases are a heterogeneous group of enzymes classified according to what 
subclasses of β-lactams they are degrading through hydrolyzing. As mentioned earlier, 
ESBLs degrade a wide range of different β-lactams (47, 63, 64). Other groups of β-
lactamases that also degrade mecillinam are for instance carbapenemases (31, 71) and 




Alteration in the cell wall composition is another resistance mechanism of mecillinam. An 
example of this is modification of PBPs, which may be caused by mutations of different 
resistance-encoding genes that confer resistance. PBPs have a distinct role in cell shape, 
division and elongation. Even in the absence of PBP 2 activity, high levels of cell division 
proteins (e.g. FtzQ, -A and -Z, and MrdA and -B) (65, 68, 74) and positive effector for 
septation (e.g. ppGpp, a signal for the stringent response) (69) are observed, and this effect is 
suggested to be a compensation mechanism, where cell division is restored (75).  
Reduced expression of cell wall porins is the third resistant mechanism of mecillinam. 
Gram-negative bacteria are more impermeable than Gram-positive due to its double layer of 
cell membranes. The outer cell membrane of Gram-negative bacteria forms a permeable 
barrier, thus hydrophilic antimicrobials may cross the outer membrane by diffusing through 
outer membrane porin proteins. There are three major porin types in E. coli: OmpC, OmpF 
and PhoE (76). The first two are the most important for uptake of β-lactams (77). Thus either 
the down-regulation of porins or the replacement of porins with more selective channels will 
result in decreased influx of antimicrobial agents (78). 
Over-expression of efflux pumps is the last one of the resistance mechanisms. Diffusion of 
antimicrobials through the outer cell membrane to reach its target in the periplasm may be 
stalled by efficient removal by efflux pumps. There are different types of efflux pumps, such 
as the resistance-nodulation-division (RND) efflux pumps, which include the AcrAB-TolC 
and AcrAD-TolC. Mutations in one or more efflux expression regulators may cause an 
increase in their expression and confer resistance (79). 
 
As mentioned, the prevalence of resistance to mecillinam has remained low in the world in 
general. This is contradictory comparing to in a laboratory settings where the frequency of 
mutations is high (12). To explore this matter, Thulin et al. displayed an overview of different 







Table 1: The known mecilliam resistance-encoding genes and their functions. Adapted and modified from: (12). 
Genes(s) 
(alias[es]) 
Function References  
mrdA (pbpA) Cell division and elongation (68, 80)  
mrdB (rodA)  (68, 81)  
mreB (envB)  (67)  
mreC  (67)  
ftsQ  (65, 74)  
ftsA  (65, 74)  
ftsZ  (65, 74)  
rpoB RNA synthesis (82)  
cysB Cysteine biosynthesis (83, 84)  
cysE  (83, 84)  
argS (lov) tRNA synthetases (69)  
alaS  (69)  
slt Transglycosylation (84)  
lon Rcs regulatory system (85)  
rcsB  (66, 85)  
rcsC  (66, 85)  
yrfF (mucM, 
igaA)  
 (85)  
cyaA  Global regulation (86, 87)  
crp   (86, 87)  
spoT ppGpp degration and 
synthesis 
(12)  
rfa, rfb, rfc Lippolysaccharide (12)  
galE  (12)  
aroK Shikimate kinase (11)  
 
Their work revealed that the frequency of mutations leading to mecillinam resistance is very 
high in in vitro selection-experiments compared to clinical settings, where resistance 
development seems to be rather uncommon. They suggested that mutations, which confer 
resistance in laboratory selections, have higher fitness costs. Hence their growth rates are 
reduced below the threshold level needed for stable maintenance in the bladder during 
treatment. 
In this project, the following genes were chosen for close scrutiny; mrdA, thrS, aspS and gtlX. 
These genes encode PBP 2, threonyl-tRNA synthetase, aspartate tRNA ligase and glutamyl-




resistance, hence this work may reveal the resistance mechanism in the mecillinam resistant 
isolates. The selection of these genes was based on the work by Thulin et al. in which the 
respective genes showed a high frequency of mutations observed in laboratory settings (12) 
and on the basis of the gene encoding for the drug target of mecillinam.  
 
 
1.8 Antimicrobial susceptibility testing  
Antimicrobial susceptibility testing (AST) is central in the current project. Therefore the 
following is an introduction to different methods, which may be used for determination of 
antimicrobial susceptibility in vitro, with a focus on the methods used in this project. 
Microorganisms can be tested for their susceptibility to a certain antimicrobial using various 
laboratory techniques. Commonly, these are used to determine the minimum inhibitory 
concentration (MIC) (88). The MIC is defined as the lowest antimicrobial concentration that 
prevents growth of the microorganism. The MIC is an important result in diagnostic 
laboratories to confirm antimicrobial resistance, but can also be used to determine the potency 
of novel antimicrobials (88). There are different methods to perform AST: 
Disk diffusion: One of the oldest methods and remains as one of the most widely used AST 
in routine clinical laboratories (89). The method is based on disks containing antimicrobials, 
which are applied on MHA plates with bacterial inoculum and are incubated overnight. If an 
antimicrobial is effective against the bacteria, either bactericidal or bacteriostatic, there will 
be an area around the disk where bacteria growth is not visible. The size of the clear area 
(zone of inhibition) is dependent on how effective the antimicrobial is against that bacteria, 
thus an effective antimicrobial will create a larger zone. 
E-test: This method confirms the susceptibility of organisms to a certain antimicrobial agent 
by measuring the MIC (88). The strips used in the MIC-test have predefined and continuous 
concentration gradient of different antimicrobial agents. When applying these strips to 
inoculated agar plated and incubated, an eclipse of inhibition that intersects the strips will 
occur. The MIC value (µg/ml) can be read using the scale on the strip.  
Micro broth dilution: This method is performed by using multiple microtiter plates filled 




made in the plate and followed by adding the bacterial inoculum of interest. The optical 
density is measured the day after the incubation to observe the visible growth of the bacteria.  
For the current project, both MIC-test and micro broth dilution have been used. The MIC-test 
was to confirm whether the isolated phenotypes were resistant or susceptible to mecillinam. 
Micro broth dilution with the IC90-assay was used to describe possible collateral sensitivity 
and collateral resistance networks in mecillinam resistant isolates. 
 
1.8.1 EUCAST 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is a committee 
that published breakpoints and technical aspects of phenotypic in vitro AST in Europe (88). 
These clinical breakpoints are used in clinical laboratories, providing guidance to clinicians 
with respect to the potential use of agents for treatment in patients. The organization publishes 
MIC breakpoint interpretations based on several factors, including pharmacokinetic and 
pharmacodynamics data, clinical studies, resistance mechanisms, commonly used dosing 
regimens and the WT MIC distributions for relevant species of organisms (91).  
In the latter, the highest MIC within the WT MIC distribution is used as the epidemiological 
cut-off value (ECOFF) (92). The ECOFF is used as a tool to distinguished isolates without 
(WT) and with acquired resistance mechanisms (non-WT) to a given antimicrobial agent. 
Isolates with a MIC above the ECOFF (hence likely to possess resistance mechanisms) are 
often clinically resistant. Together, ECOFFs and clinical breakpoints are used to determine 
the rate of resistance development. 
The clinical breakpoints are categorized into three groups:  
Ø Susceptible: The organism should respond to the therapy using recommended 
antimicrobial dosage for the given site of infection and species. 
Ø Intermediate: The organism’s MIC approaches or exceeds the threshold for normal 
antimicrobial dosing, but clinical response is possible with higher doses or if the 
antimicrobial concentrates at the site of infection. 





Depending on which type of microorganisms and antimicrobial agents are being tested, the 
MIC-value will determine the sensitivity profile of the microorganism according to the 
EUCAST clinical breakpoints (93).  
 
 
1.9 ECO-SENS projects 
The first international survey to investigate the prevalence and susceptibility of pathogens 
causing community-acquired uncomplicated UTIs is the ECO-SENS Project (94). There have 
been two ECO-SENS studies (62, 94). The first one took place in 1999-2000 and included 
4734 women, not older than 65 years, from 16 European countries and Canada (94). Patients 
with symptoms of an acute UTI provided a midstream urine sample, which was tested for the 
presence of bacteria and the susceptibility of the isolated bacteria to 12 antimicrobials was 
determined. The conclusion of the surveillance study indicates that antimicrobial resistance 
was lowest in the Nordic countries and Austria and highest in Portugal. 
The second ECO-SENS study was in 2008-2009 (62). This time, the surveillance study only 
included five countries and 1697 women gave urine samples for bacterial isolation and 
antimicrobial susceptibility testing to 14 antimicrobials. The countries were selected to 
represent areas of Europe, which were indicated to have more (Greece and Portugal) or less 
(the UK, Austria and Sweden) problems with resistance. In this project, 11 resistance isolates 
with ESBLs were identified, compared to the previous ECO-SENS study where there were 
none. 
In the first ECO-SENS study in 2000, AMR of E. coli to mecillinam was less than 3%, and 
similarly low for ciprofloxacin, gentamicin and nitrofurantoin. However, ciprofloxacin 
resistance was apparent in Portugal (5,8%). The second surveillance study in 2010 also 
showed low AMR, including mecillinam, gentamicin and nitrofurantoin in E. coli, less than 
2%. While ciprofloxacin and trimethoprim resistance had increased between the first and the 
second surveillance study; 1,1% to 3,9% for ciprofloxacin and 13,3% to 16,7% for 
trimethoprim. In both studies amoxicillin, chloramphenicol and tetracycline were not 
included. 




2 HYPOTHESIS AND AIMS 
2.1 Hypothesis 
Collateral sensitivity networks have been demonstrated for single isolates of E. coli. We 




In this project we aim to explore the generality of the concept of collateral sensitivity in 
clinical urinary tract isolates of E. coli from the ECO-SENS collection. With the emergence 
of increased multi-drug resistance (MDR), we aim to inform recommendations for novel 
treatment strategies to improve efficacy of treatment for UTIs and to prevent further 
resistance development. Furthermore, we want to investigate the underlying mechanisms of 






3.1 Bacterial strains 
All of the bacterial strains used in this project belonged to the ECO-SENS strain collection 
described previously (62, 94). In this project 15 different ECO-SENS isolates from Greece, 
Portugal, Sweden and the UK were used to make mecillinam resistant mutants, as shown in 
Table 2. Ten of our resistant mutants were selected for further analysis. All isolates used are 
pan-susceptible, meaning the isolate is susceptible to all antimicrobial agents, and plasmid-
free. 
Table 2: ECO-SENS isolates employed in this project. Isolates in bold were used for further analysis. Sequence type 
was determined by multilocus sequence typing and phylogroup was determined by triplex PCR-based method (95). 
Name Sequence type Phylogroup Year Country 
K56-5 998 B2 2000 Greece 
K56-17 73 B2 2000 Portugal 
K56-18 998 B2 2000 Portugal 
K56-20 127 B2 2000 Portugal 
K56-23 73 B2 2000 Sweden 
K56-24 73 B2 2000 Sweden 
K56-25 73 B2 2000 Sweden 
K56-30 1161 B2 2000 Sweden 
K56-31 638 B2 2000 The UK 
K56-66 372 B2 2007-2008 Sweden 
K56-69 1230 A 2007-2008 Sweden 
K56-71 607 A 2007-2008 The UK 
K56-76 978 B2 2007-2008 The UK 
K56-77 1236 B2 2007-2008 The UK 





3.2 Buffers, growth media and other chemicals 
Table 3: An overview of growth media and other chemicals used in this project. 








680 mg sodiumchloride were 
added to 80 mL ddH2O. 
RT Fluka 
80% glycerol 86-89 % glycerol 
ddH2O 
54 mL glycerol were added to a 
container and adjusted to 100 
mL with ddH2O. 
RT Sigma-Aldrich 
LB broth LB broth 
ddH2O 
5 g LB broth were added to 200 
mL ddH2O. 







12 g Select agar and 20 g LB 
broth were added to 800 mL 
ddH2O. 
-4°C BD DifcoTM, 
Miller 
Sigma-Aldrich 
MH II agar 
(MHA) 
MH II agar 
ddH2O 
7,6 g MH II agar were added to 




Mecillinam 100 mg 
Ultra Purewater 
100 mg mecillinam were 




MHA-Mec16 MH II agar  
Mecillinam  
1 mg/mL 
3,2 mL mecillinam 1 mg/mL 





Glacial acid (100%) 
0,5 M EDTA (pH 
8,0) 
ddH2O 
242 g Tris-base were added to 
600 mL of ddH2O. Then 57,1 
mL glacial acetic acid and 100 
mL of 0,5 M EDTA were 
added in the mix. The mix was 
brought to a finale volume to 1 


















70 mL of 96% EtOH were 




3.3 Polymerase chain reactions and DNA sequencing 
Some of the primers used in this project have been published previously (12) and others were 




and gtlX. These genes encode PBP 2, threonyl-tRNA synthetase, aspartate tRNA ligase and 
glutamyl-tRNA-synthetase respectively. 
Each gene required 2-3 primer sets for complete coverage of the gene of interest (Table 4). 
Primers were diluted with nuclease-free water (Thermo Fisher Scientific), first to a stock 
concentration of 100 µM and then to a final working stock solution of 10 µM. The same 
primers were used for PCR and sequencing.   
 
Table 4: The primers used in this project. 
Primer 
name 





mrdA-F1 GTGCTGGTCGCAGAGAGTC -20°C 719 bp mrdA  This study 
mrdA-R1 TTACCGATATCATGCGTTGC -20°C  This study 
mrdA-F2 CACGTCATCGGCTATGTGTC -20°C 767 bp This study 
mrdA-R2 ATGTTGCCGGAACGTTCTTC -20°C  This study 
mrdA-F3 CCGAATGGATGGGTAAATTC -20°C 750 bp This study 
mrdA-R3 ATTGTGGGATCGAGATGGAC -20°C  This study 
thrS-F1 CTCCGGCTTCTTCTGCTT -20°C 633 bp thrS  (12) 
thrS-R1 CAGCTGGACTTCTCTTTGCC -20°C  This study 
thrS-F2 TTGCGCGGTGAATCATTACC -20°C 834 bp This study 
thrS-R2 CTGGAAGAAGCCGCGAAAC -20°C  This study 
thrS-F3 ACATTTTGTTGTTGCTGTCGC -20°C 796 bp This study 
thrS-R3 TAACATCGCTCAACCGGG -20°C  (12) 
aspS-F1 AATTTCCAGTATAATAGCCGCC -20°C 733 bp aspS  (12) 
aspS-R1 AAACCGGACATCATCAGCAG -20°C  This study 
aspS-F2 GACTACCTGGTGCCTTCTCG -20°C 733 bp This study 
aspS-R2 GACCAAGGTCTTTACCCACTTTC -20°C  This study 
aspS-F3 GGTGCCGACAACAAGAAAAT -20°C 704 bp This study 
aspS-R3 CCTCTTCGTTGACTGCCTTC -20°C  This study 
gltX-F1 GAATCAGGCGGGAGTGATAG -20 °C 862 bp gltX  This study 
gltX-R1 TTCTGGCAAATAACCGTCATC -20 °C  This study 
gltX-F2 TTTACGCGCACGTTTCTATG -20 °C 828 bp This study 
gltX-R2 CCGTCTCGATATTGACGAATC -20 °C  This study 
 
	
Table 5: Chemicals and enzymes for the PCR mastermix and sequencing reaction. 
Name of component  Storage 
temperature 
Producer 
Nuclease-free water RT Thermo Fisher Scientific 
5X Phusion HF buffer -20°C New England BioLabs® 
10 mM dNTPs -20°C New England BioLabs® 
Template DNA -80°C - 
Phusion DNA Polymerase  -20°C New England BioLabs® 
Big Dyea 4°C - 
5X Sequencing buffera 4°C - 




3.4 Agarose gel electrophoresis 
Listed in Table 6 are the different reagents for agarose gel electrophoresis that were used in 
this project.  
Table 6: Different reagents for agarose gel electrophoresis.  
Name of reagent Content Storage 
temperature 
Producer 
1X loading buffer Dilute 6X loading buffer 1:6 with 
sterilized ddH2O. 
RT - 
SmartLadder - 2-8°C EuroGentec 
Agarose 1% gel 1 g dissolved in 100 mL 1X TAE buffer. 2-8°C SeaKem, 
USA 




3.5 Antimicrobial agents for MIC and IC90 determination 
Micro broth dilution with IC90-assay was performed to determine collateral sensitivity profiles 
of mecillinam resistant isolates. The list over different antimicrobial agents employed and 
what kind of solution was used to dissolve them in are displayed in Table 7. 
Table 7: List over antimicrobial agents used in IC90-assay. 
Antimicrobial agent Producer Catalog no. Resuspend in  
Amoxicillin Sigma-Aldrich A0800000 Phosphate buffer, pH 6.0, 0.1 mol/L 
Chloramphenicol Sigma-Aldrich C0378 95% EtOH 
Ciprofloxacin Biochemika 17850 0,1N hydrochloride (HCl) 
Gentamicin Sigma-Aldrich G3632-1G MilliQ-water 
Mecillinam Sigma-Aldrich 33447-100MG ddH20 
Nitrofurantoin Sigma-Aldrich N7878-25g DMSOa  
Trimethoprim Sigma-Aldrich T7883-25g DMSOa  
Tetracycline Sigma-Aldrich T3383-25g MilliQ-water 
a Dimethyl sulfoxide 
MIC-testing was performed to determine the antimicrobial susceptibility of different isolates 
in static selection. The MIC-strips of mecillinam used in this study are displayed in Table 8.  
Table 8: MIC-strips of mecillinam used for MIC-testing. 
Antimicrobial agent Storage temperature Concentration gradient (µg/mL) Producer 





3.6 Various kits used in this project 
Different kits were used for DNA isolation of the strains and isolation of DNA from agarose 
gels as displayed in Table 9. 
Table 9: List over different kits used in this project. 
Kit Catalog No. Storage 
temperature 
Lot No. Producer 
QIAquick Gel Extraction Kit 28706 RT 127128966 QIAGEN 
GenElute Bacterial Genomic 
DNA Kit 
1002047701 RT SLBN5542V Sigma-Aldrich 
BigDye® Terminator v3.1 
Cycle Sequencing Kit 





3.7 Equipment employed in this project 
Following are a list over different equipment used in our project for IC90-assay, DNA 
isolation, isolation of DNA from agarose gel and Nanodrop spectrophotometer, displayed in 
Table 10. 
Table 10: List over various equipment employed in this project. 
Name of equipment  Producer Order/Part No. 
Microplater Shaker TiMix 5 control Edmund Bühler GmbH 6167700 
VersaMax ELISA Microplate Reader Molecular Devices VERSAMAX 
Heraeus Biofuge Pico Kendro® 75003235 







4.1 Bacterial cultivation 
Bacterial isolates used in this project were cultured on appropriate agar plates or in liquid 
medium. Both techniques are described below. 
 
4.1.1 Streaking and isolating bacteria on solid medium (agar) 
For the streaking on agar plates, an inoculation loop was used to i) dip into a bacterial culture, 
ii) scrape a colony of an agar plate or iii) scrape from the surface of a freeze culture. Then the 
loop was dragged across the surface of the agar horizontally back and forth until ¼ of the 
plate had been covered; zone 1.  With the same loop it was dragged across the same section, 
but from another angle this time to get complete coverage of the area/zone 1. The plate was 
then turned 90 degrees. Starting from zone 1, a new loop was dragged zigzag across the plate 
until covering 1/3 of the plate (the loop only crossed zone 1 3-4 times); zone 2. This step was 
repeated once more but now from zone 2, only 2-3 times from that zone, and with bigger 
space between the zigzag motions. Finally the plate(s) was incubated over night (12-18 hours) 
at the appropriate temperature (usually 37°C). See Figure 8 for division of the various zones. 
	
Figure 8: An agar plate showing its different streak zones. 
 
4.1.2 Liquid cultures 
Bacteria can be grown in liquid cultures. The desired bacteria were transferred and suspended 
in a tube containing 4 mL LB broth using an inoculation loop. The tube(s) was incubated 




4.2 Storage of the bacterial isolates – Freeze stock cultures 
For long term, stable storage of the bacterial isolates used and the mutants generated in this 
project, freeze stock cultures were used.  
Freeze stock cultures were prepared for WT strains and mecillinam resistant mutants for long 
time storage of bacteria strains. Overnight culture(s) of the respective strain(s) was incubated 
over night at the appropriate temperature (37°C), 225 rpm. A tube (Cryo freeze tubes VWR 
International, USA) was added 250 µL of the inoculate and 750 µL of 80% glycerol, resulting 
in a finale concentration of 20% glycerol. The tube was then stored at -80°C. 
 
 
4.3 Preparation of bacterial growth media 
Bacteria were cultivated in either liquid or solid media. Most of the media were prepared in 
the lab. MH broth used for the IC90 assays were bought from the University Hospital of 
Northern Norway (UNN) in Tromsø to ensure stable quality throughout the experiments. 
Antimicrobial stock solutions were prepared in the lab by the technical staff for the IC90 
assays for common use.  
 
4.3.1 Liquid medium 
The liquid media were prepared by adding MH II or LB powder in ddH2O as specified by the 
manufacturer (Table 3), and then autoclaved at 121°C with 100 kPa for 20 minutes. The 
liquid media were then cooled down to the appropriate temperature (55°C) before use. 
 
4.3.2 Agar plates with and without antimicrobial drugs 
MHA and LBA were prepared as specified by the manufacturer adding appropriate amounts 
of agar. After autoclaving of the liquid medium, the solution was cooled down to below 55°C 
and the appropriate volume of thawed mecillinam stock solution was added to desired finale 




mL MHA. Afterwards the solution was poured in empty sterile petri dishes and cooled/dried 
overnight. The MHA-Mec plates were stored at 4°C for up to one week. 
 
4.3.3 Antimicrobial stock solution 
Mecillinam powder was dissolved in ddH2O to a finale concentration of 1 mg/ml. Thereafter a 
0,2 µM filter unit was used for sterile filtration. Small volumes were aliquoted of the stock 
solution into sterile eppendorf tubes (850 µL) or Nalgene cryovials (3,5 ml). Single use vials 
were stored at -20°C. 
Other antimicrobial stock solutions prepared were dissolved and diluted in appropriate media 
according to Clinical and Laboratory Standards Institute (CLSI) or manufacturer’s guidelines. 
More details are given in the materials chapter. 
 
 
4.4 Static antimicrobial resistance selection and mutation frequency 
To acquire spontaneous antimicrobial resistant isolates, in this case of E. coli, static selection 
under antimicrobial pressure was used for this project. Clinically resistant mutants will 
henceforth be mentioned as resistant mutants in this project. 
 
4.4.1 Inoculum for selection of mecillinam resistant mutants 
A streak for isolation of the bacterial isolate(s) of interest was prepared from freeze stock 
cultures by scraping a small (5-10 µL) sample of the frozen stock and struck on LBA plate(s). 
The frozen stock was restored immediately to -75°C, and the plate(s) was then incubated at 





4.4.2 Making mecillinam resistant mutants with selective plates 
10-20 sterile glass beads were added to an MHA-Mec16 plate, which was pre-warmed to RT. 
100 µL of undiluted overnight culture (after 18±2 hours) were added on the MHA-Mec16 
selective plate(s) and was shaken in horizontal plane until inoculum had been completely 
absorbed. The plates were incubated (24-48 hours) until visible growth was present. 
 
4.4.3 Determination of the initial inoculum with non-selective LBA plates 
A 96-well plate was used to fill 6 wells per sample with 900 µL of sterile 0,85% saline. 100 
µL of the overnight culture were pipetted into the first well of the dilution series. The well 
was mixed by pipetting 10-20 times and then the pipet tip was discarded. With a new tip, 100 
µL was moved from well 1 to well 2. Again the well was mixed by pipetting 10-20 times and 
the pipet tip was discarded. These steps were repeated until the entire series had been 
completed to a finale dilution factor of 10-6. LBA plates were pre-warmed to RT (2 plates for 
each strain) and 10-20 sterile glass beads were added. 100 µL dilutions, 10-5 and 10-6, were 
added onto each plate and shaken horizontally until the inoculum had been completely 
absorbed. These dilutions were chosen to give countable amounts of colonies on the plates. 
Then the glass beads were removed.  The plates were incubated at the appropriate temperature 
(37°C) until visible growth was present (for 24-48 hours) (Figure 9). 
 





4.4.4 Determination of estimated mutation frequency 
After day 1, colony-forming units (CFUs) was counted for each dilution and each sample on 
LBA plates. The plates were thereafter incubated additionally until visible growth was present 
on the selective plates, and colonies were counted once more. CFUs of mecillinam resistant 
mutants were counted on day 1 or 2, and the mutation frequency was calculated. The 
inoculum was calculated from CFU counts from plates incubated for the same amount of time 
as the selective plates. The following formula was used for the calculation of mutation 
frequency:  
Mutation frequency =  #mutants on MHA-Mec16 plate




4.4.5 Purification and storage of mecillinam resistant isolates 
Single isolated colonies were picked from MHA-Mec16 plates (either on day 1 or day 2) and 
struck for isolation on new MHA-Mec16 plates (one plate per single isolated colony, and at 
least 3 colonies were purified). When possible, different phenotypes where chosen and 
observations of the colony morphologies were noted. After incubation of the plates at 
appropriate temperature (37°C for 24-48 hours depending on growth), a well-isolated single 
colony from each streak for isolation plate was picked with a sterile loop and inoculated into 4 
mL LB broth. If the colonies were not uniform/homogenous, streaks for isolation were 
repeated. 3 isolates per parental WT isolate were picked from the plates, inoculated in LB 
medium and incubated overnight at 37°C with shaking at 225 rpm. Incubation continued until 
visible growth was present, typically 18-24 hours. This culture was used to prepare freeze 
stocks. 
 
4.4.6 Confirmation of species 
Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) is a method 
combining mass spectrometry and an identification system based on molecular weight (96). 
The method is based on the samples being mixed with a matrix. This was accomplished by 




marked positions on the target plate. 1 µL matrix was added in every position when all the 
samples were applied (recommended within 10 min). Thereafter the target plate was allowed 
to air dry completely before analyzing. The matrix would absorb the energy from ionizing 
lasers and lead to ionization and the release of matrix/sample-crystals. An electrical field 
would migrate the ionized proteins through the “flight-tube”. Different mass would get to the 
detector with different times; hence the time was proportional with the mass. This specificity 
was utilized to compare the time, which functioned as a “fingerprint”, with a database and the 
identification system would give the sample an ID of a species. A score indicated the 
probability for the right identification. Scores over 2,0 indicates reliable identification on a 
species level (Appendix B). 
 
 
4.5 Antimicrobial susceptibility testing 
Microorganisms can be tested for their susceptibility to a certain antimicrobial with measured 
MIC (88). For the current project both MIC-strip testing and IC90-assay with micro broth 
dilution were used for determining the antimicrobial susceptibility of the bacteria. IC90 is the 
lowest inhibitory concentration of the antimicrobial that inhibited 90% of the growth of the 
tested isolate (97). Breakpoints of the tested microorganisms are being compared to 
EUCAST, which will determine the susceptibility profile of the microorganism (88).  
 
4.5.1 MIC-strip testing 
MIC-test is utilized to check the organism´s susceptibility to an antimicrobial agent, in this 
context the antimicrobial agent is mecillinam. The strips used in the test assay have a 
predefined and continuous concentration gradient of mecillinam (0,016-256 (µg/ml) . When 
applying these strips to inoculated agar plated and incubated, an ellipse of inhibition 
intersecting the strips will occur. The MIC-value (µg/mL) can be read on the strip scale.   
The bacterial colonies on the LBA plate(s) were selected using a sterile cotton swab. The 
cotton swab with bacteria was swabbed in sterile saline 0,85% to make a 0,5 McFarland 
medium. A cross was made on a new MHA plate with a new cotton pad, which was dipped in 




cotton swab it was moved from the edge of the plate to the middle with slow motion. The tip 
was turned and moved slowly backwards to the initial point (approximately 10 seconds each 
way). A MIC-strip of mecillinam was placed on the plate with sterile tweezers, and incubated 
at 37°C with ambient air (18 hours), see Figure 10. The observed MIC-value was compared to 
the clinical breakpoints defined by EUCAST to determine whether the respective bacterial 
isolate was resistant to mecillinam or not (Appendix D). 
 
 




4.5.2 IC90 determination 
As displayed in Table 11, the respective eight antimicrobial agents were chosen for the IC90-
assays; amoxicillin, chloramphenicol, ciprofloxacin, gentamicin, mecillinam, nitrofurantoin, 
tetracycline and trimethoprim.  
Table 11: List of antimicrobial agents employed in this project. 
Antimicrobial agent Abbreviation Class Target 
Amoxicillin AMX β-lactam Cell wall 
Mecillinam MEC β-lactam Cell wall 
Ciprofloxacin CIP Quinolone Nucleic acid synthesis, DNA gyrase 
Gentamicin GEN Aminoglycoside Protein synthesis, 30S 
Tetracycline TET Tetracyline Protein synthesis, 30S 
Chloramphenicol CHL Miscellaneous Protein synthesis, 50S 
Nitrofurantoin NIT Miscellaneous Multiple 
Trimethoprim TMP Dihydrofolate reductase 
inhibitor 







Initially, bacterial isolate(s) of interest, as well as the control isolates ATCC 25922 and K56-
44 (mecillinam resistant mutant), from freeze stocks were streaked on LBA plates and 
incubated overnight. Mecillinam resistant mutants and the parental WTs were always tested 
together in the same assay. There were performed two replicates of each isolate, with 2-fold 
or 1,5-fold antimicrobial dilutions. A 96-well microtiter plate was loaded with MH broth as 
shown in Table 12 and Table 13, depending on which fold change that was being used. 
 
Table 12: 96-well plate filled with MH broth for 2-fold CS/CR. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
B 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
C 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
D 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
E 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
F 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
G 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
H 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
Table 13: 96-well plate filled with MH broth for 1,5-fold CS/CR. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
B 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
C 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
D 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
E 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
F 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
G 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
H 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 200 µL 
 
A working stock of the antimicrobial to be tested at 2x the highest concentration was 
prepared. The specific MIC testing guidelines and/or manufacturer’s guidelines were 
followed to ensure correct antimicrobial stock solution was made. Dilutions of the stock to the 
2x highest concentration were done in MH broth. For 2-fold, 200 µL of the antimicrobial 
working stock was added in column 2 (Table 14), either with different antimicrobials or 
different antimicrobial concentrations. For 1,5 fold 150 µL of the same working stock was 
added into the wells of column 3 as well (Table 15). ATCC strain and K56-44 were included 





Table 14: 96-well filled with antimicrobial working stock for 2-fold CS/CR. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A  200 µL           
B  200 µL           
C  200 µL           
D  200 µL           
E  200 µL           
F  200 µL           
G  200 µL           
H  200 µL           
Table 15: 96-well filled with antimicrobial working stock for 1,5-fold CS/CR. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A  200 µL 150 µL          
B  200 µL 150 µL          
C  200 µL 150 µL          
D  200 µL 150 µL          
E  200 µL 150 µL          
F  200 µL 150 µL          
G  200 µL 150 µL          
H  200 µL 150 µL          
For 2-fold, 100 µL was taken from column 2 and mixed with the wells of column 3. It was 
pipetted 10-15 times to ensure thorough mixing. The content was completely expelled of the 
tips into column 3 and 100 µL was taken from column 3 to column 4. The mixing and serial 
dilutions of the antimicrobial were continued, and 100 µL of the mixture was discarded at the 
end from column 11. 
For 1,5-fold, 100 µL was taken from column 2 and mixed with the wells of column 4. It was 
pipetted 10-15 times to ensure thorough mixing. The content was completely expelled of the 
tips into column 4 and 100 µL was taken from column 4 to column 6. The mixing and serial 
dilutions of the antimicrobial were continued, and 100 µL of the mixture was discarded at the 
end from column 10. The same mixing and serially dilution process were repeated, but 
starting from column 3 column to 5 until reached column 11. Here 100 µL was discarded as 
well. 
Preparation of a 0,5 McFarland in 0,85% sterile saline with a few isolated colonies from LBA 
plates was done. The 0,5 McFarland was diluted 1/1000 into MH broth by adding 5 µL into 
4,995 mL MH broth. Lastly, 100 µL of the bacterial isolate inoculum was added to the 




Table 16: A schematic illustration of added diluted experimental isolates, each row containing the same type of isolate. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
B 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
C 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
D 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
E 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
F 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
G 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
H 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL  
The 96-well plate was incubated at 37°C with continuous shaking at 700 rpm for 18 hours. 
For the slow growing isolates incubation continued up to 42 hours. By using a plate reader, 
the A600nm read (using SoftMax® Pro Software v5.4.1) was taken after 18 hours (additional 
after 24 and 42 hours for some strains). The measurements were used to calculate the IC90, 
and background-subtracted. The concentration at which %inhibition was ≥90 was calculated 
with the following formula: 
% !"ℎ!"!#!$% = 1 − !600 !"#$ !"#$!#%!600 !"#$%$&' !"#$%"&  ! 100  
 
Based on the calculations of the IC90-values, the MIC-value for each isolate was determined. 
To categorize whether an isolate was resistant or susceptible for the respective antimicrobial 
agent, the MIC-values of the parental WTs and mecillinam resistant mutants were compared 
to the clinical breakpoints defined by EUCAST. The control strains were also compared for 
whether they were in range or not (Appendix D). 
 
 
4.6 Preparation of genomic DNA for PCR 
Isolation of bacterial DNA was prepared to obtain pure extraction of DNA from a variety of 





4.6.1 DNA extraction using the GenElute Kit (Sigma) 
DNA isolation with GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich, 
NA2100/2110/2120) is a method, which gives high quality DNA with high degree of purity 
providing genomic bacterial DNA suitable for PCR and WGS. DNA isolation was conducted 
primarily according to the description of the manufacturer.  
The bacterial isolate(s) of interest was inoculated in 5 mL LB media and incubated overnight 
at the appropriate temperature (37°C) with shaking at 225 rpm (an LB control was always 
included from each batch of medium). 1,5 mL of overnight culture was pelleted by 
centrifuging for 2 minutes at 13000 rpm in Heraeus microfuge pico. The supernatant was 
poured off afterwards. Resuspension of the pellets was done thoroughly in 200 µL of 100 
mg/mL of lysozyme in the solution Gram positive lysis solution, which was provided in the 
kit (prepared fresh), and incubated for 30 minutes at 37°C. 20 µL RNase A solution was 
added to each sample, and they were incubated for 2 minutes at RT. Thereafter 20 µL of 20 
mg/mL Protein K solution were added to the mix, followed by 200 µL of Lysis solution C. 
The mix was vortexed thoroughly and incubated at 55°C for 10 minutes. For the column 
preparation, 500 µL Column Preparation Solution was added to each pre-assembled GenElute 
Miniprep Binding Column and centrifuged at 13000 rpm for 1 minute. The eluate was 
discarded. The binding was prepared by adding 200 µL EtOH 96% to the lysate and mixed 
thoroughly by vortexing. Afterwards the entire content of the tube was transferred to the 
column and centrifuged at 13000 rpm for 1 minute. The collection tube containing the eluate 
was then discarded. In the washing process, 500 µL Wash Solution was added to the column 
and centrifuged for 1 minute at 13000 rpm.  The collection tube was discarded and the 
column was placed in a new 2 mL-collection tube. In the second wash 500 µL Wash I 
Solution was added to the column and centrifuged for 3 minutes at 13000 rpm. Additional 1 
minute of centrifuging was performed to remove residual EtOH. The collection tube 
containing the eluate was then discarded and the column was again placed in a new 2 mL 
collection tube. Lastly, DNA was eluated with 100 µL of 10 mM Tris-base directly onto the 
center of the column and incubated for 5 minutes at RT, and then centrifuged for 1 minute at 
13000 rpm. DNA purity and concentration was determined on Nanodrop (ND-1000 v3.8.1), 





4.6.2 Determination of DNA concentration and purity with Nanodrop 
Nanodrop spectrophotometer (Nanodrop®, ND-1000 V3.8.1) was used to determine the 
concentration and purity of the DNA. The spectrophotometer was cleaned with ddH2O and 
blanked with the appropriate solution, and each sample was measured. The result from the 
spectrophotometer shows concentration of DNA in µg/ml, 260/280- and 260/230 ratios. The 
concentration of DNA was used to determine the amount of DNA for e.g. BigDye® 
Terminator v3.1 Cycle Sequencing Kit. 260/280 ratios described the purity of the isolated 
DNA. "Pure" DNA should have a ratio around 1.8. If the values were lower than 1.8, it 
indicated the presence of protein, phenol or other contaminants. While 260/230 ratios were to 
measure the purity of the nucleic acids. 260/230 ratios were commonly in the range of 2.0-
2.2. If the values were lower, it indicated the presence of contamination.  
 
 
4.7 Polymerase chain reaction using Phusion® High-Fidelity DNA 
Polymerase 
Polymerase chain reaction (PCR) was used to amplify a specific gene of interest, in this case 
mrdA which encodes PBP 2, the drug target for mecillinam. This is to find genomic mutations 
in mecillinam resistant mutants of E. coli, which may confer resistance. 
PCR is an amplification technique of small amounts of genetic material. The principle is 
based on amplification of a sequence of DNA, generating enormous amounts of copies of that 
particular DNA sequence. There are three main steps in PCR based on repeated amplification 
cycles. The first involves denaturation of the double stranded DNA (dsDNA) where it is 
melted and becomes single stranded DNA (ssDNA). In the second step we have annealing of 
the primers to the complementary regions of the ssDNA. The temperature in this step varies 
from each primer and has to be lower than the melting temperature of the primers (Tm) hence 
they can bind properly to the template. The last step involves polymerase extension of the 
ssDNA, which completes the amplifications of the wanted DNA segments.  For this project 
Phusion® High-Fidelity DNA Polymerase was chosen for DNA synthesis. 
Phusion® High-Fidelity DNA Polymerase was the polymerase which was chosen for the 




Phusion® High Fidelity DNA Polymerase reaction were prepared by using DNA isolation 
with GenElute Kit (section 4.9).  
 
4.7.1 Preparation of mastermix for phusion PCR 
The mastermix recipe is given in Table 17. All the ingredients were stored at -20°C, and the 
mastermix was prepared fresh for each PCR. The ingredients were thawed on ice, and 
everything was kept on ice during the procedure.  
Table 17: Names and the quantity of each component per 20 µL reaction.  
Component 20 µL reaction 
Nuclease-free water to 20 µL 
5X Phusion HF buffer 4 µL 
10 mM dNTPsa 0,4 µL 
10 µM Forward primer 1 µL 
10 µM Reverse primer 1 µL 
Template DNA 2 µL 
Phusion DNA Polymerase  0,2 µL 
a Containing the four deoxyribonucleoside triphosphates (dATP, dCTP, dGTP and dTTP). 
	
4.7.2 Phusion® High-Fidelity DNA Polymerase PCR 
The Phusion® High-Fidelity DNA Polymerase thermocycler program was set up as listed in 
Table 18. See Table 19 for the specific annealing temperature for each primer set. 
Table 18: Set up for the thermocycler program with Phusion® High-Fidelity DNA Polymerase. 
Step Temperature/description Time 
1 98°C 5 min 
2 98°C 10 sec 
3 See Table 19 20 sec 
4 72°C 1 min 
5 Go to step 2 Repeat cycle 29 times 
6 72°C 10 min 
7 10°C Forever 
 





Annealing temperature after 
performance of gradient PCR 
mrdA 1 58°C 59°Ca 
mrdA 2 58°C - 
mrdA 3 58°C 50°Ca 




4.8 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method for DNA separation and analysis based on their size 
and charge (98). By using an electric field the negatively-charged DNA will migrate to the 
positive electrode through a matrix of agarose. Ethidium bromide (EtBr) is added in agarose 
gel which functions as a marker by interacting itself between base pairs and emitting 
fluorescent light when exited by UV light. When placed in an electric field the DNA 
fragments will migrate to the positively charge end since the phosphate backbone of the DNA 
is negatively charged. A standard molecule marker, containing DNA molecules of different 
known sizes (200-10000 base pairs) can be compared to samples to determine the size of the 
PCR amplicons. Smaller fragments will migrate farther and faster than bigger fragments. The 
rate of migration of the DNA through the gel is determined by i) size of the molecule, ii) type 
of agarose and its concentration, iii) DNA conformation, iv) voltage applied, v) presence of 
EtBr and vi) buffers (98). 
Agarose gel was prepared by dissolving agarose (SeaKem®, USA) in 1X TAE buffer to the 
finale concentration of 1% agarose. The mix was heated in a microwave (approximately 2 
minutes) until the agarose was completely dissolved. 50 µL of 1 mg/mL EtBr was added to 
the solution when the solution was cooled down to approximately 65°C, and poured on an 
appropriate gel chamber and left to solidify (approximately 20 minutes) at RT. The solidified 
gel was then placed in an electrophoresis chamber filled with 1X TAE buffer until complete 
coverage of the gel. 2 µL PCR product was mixed with 10 µL 1X loading buffer and pipetted 
into the wells of 1% agarose gel. 3 µL of a DNA marker (Smartladder, Eurogentec USA) was 
loaded in at least one lane on each gel. Gels were run at 80 V for 1 hour. Gel Doc 
transilluminator (BioRad, USA) and the Quantity One software (BioRad, USA) was used for 
visualization of the gels and DNA bands were compared to the known DNA markers. A 
negative control of ddH2O was included for each PCR set up. 
 
 
4.9 QIAquick Gel Extraction Kit 
For some PCRs, multiple PCR products were observed of different sizes. To try to obtain pure 




out and DNA extracted using the QIAquick Gel Extraction Kit, primarily according to the 
QIAGEN’s description (99). QIAGEN is the leading provider of innovative samples and 
technologies for purpose of isolation and detection of contents in any biological sample.  
First the DNA fragment was cut out from the agarose gel and the slice was weighed. 3:1 of 
Buffer QG was added to the gel and incubated at 50°C for 10 minutes (or until the gel slice 
had completely dissolved). The tube was being vortex every 2-3 minutes during incubation to 
help dissolving. After incubation the solution was checked if it had the right yellow color 
which indicating the right pH for optimal DNA binding. 1 gel volume of isopropanol was 
thereafter added to the sample. QIAquick spin column was placed in a 2 mL collection tube 
and the sample was applied to the column and centrifuge for 1 minute. The content in the 
collection tube was discarded and QIAquick column was placed back in the same tube. 0,5 
mL Buffer QG were added to the QIAquick column and centrifuged for 1 minute. To wash, 
0,75 mL Buffer PE was added and centrifuged for 1 minute (let it stand for 2-5 minutes after 
application of Buffer PE before centrifuging). The content in the collection tube was 
discarded and the QIAquick column was centrifuged for an additional 1 minute at 13000 rpm. 
Then it was placed into a clean 1,5 mL microcentrifuge tube. To eluate DNA, 50 µL Buffer 
EB was added to the center of the QIAquick membrane, let it stand for 1 minute and 
centrifuged for 1 minute. To increase DNA concentration, 30 µL elution buffer was added, let 
it stand for 1 minute and centrifuged for 1 minute (after adding of Buffer EB, increased 
incubation time to up to 4 minutes may increase the yield of purified DNA. 
 
 
4.10 DNA sequencing 
Sanger sequencing is an automated “cycle” DNA sequencing reaction (100).  This method is 
taken advantage of chemically altered nucleotides; dideoxynucleotides tagged with 
fluorescents. While making a copy of the DNA template, the enzyme incorporates both 
nucleotides and the fluorescently tagged dideoxynucleotides. These special 
dideoxynucleotides will cause the copying process to terminate each time they are 
incorporated into the growing DNA chain. This process is repeated many times, which will 




fluorescents attached will be detected by a data analysis software to reveal the sequence of the 
original piece of DNA (100).  
 
4.10.1 Detection of genetic mutations on mecillinam resistance-encoding genes 
BigDye® Terminator v3.1 Cycle Sequencing Kit provided the required reagent components 
for the sequencing reaction in a pre-mixed format (101). The mix of BigDye v3.1 was added 
to sequencing buffer, DNA template from PCR, primer (either forward or revers) and brought 
to a finale volume of 20 µL with deionized water. 200 ng of DNA was added to each sample, 
which was calculated from the DNA concentration measured from Nanodrop. 
See Table 20 for overview of the reagents and the needed quantity of each reagent, and Table 
21 for how to perform cycle sequencing on thermal cycler. The samples were sent to the DNA 
sequencing facility at UNN for sequencing. 
Table 20: Reagents and quantity for BigDye® terminator v3.1. 
Name of reagent Quantity 
Big-Dye v3.1 1 µL 
Sequencing buffer 3 µL 
Template 200 nga 
Primer 5 mM 1 µL 
Deionized water q.s. 
Total volume 20 µL 
aNanodrop was performed for quantification of the needed volume of template. 
	
Table 21: Set up for the thermocycler program with BigDye® terminator v3.1. 
Step Temperature/description Time 
1 96°C 5 min 
2  96°C 10 sec 
3 50°C 5 sec 
4 60°C 4 min 
5 Go to step 2 Repeat cycle 24 times 
6 4°C Forever 
The Sequencher® version 4.1 sequence analysis software (Gene Codes Corporation, Ann 
Arbor, MI USA) was used to assemble sequence reads and detect regions with sequence 
variation. The genom of the mutants was compared to the parental WTs when possible, or 





4.11 Gram staining 
Gram staining was performed to see if the morphology of the mecillinam resistant mutants 
were different than that of the WT isolates. Morphology and growth of the cells were 
compared in pairs where mutants were compared to their parental WT.  
This is a common technique used to differentiate Gram-positive and Gram-negative groups 
based on their different wall constituents by coloring these cells red or violet (102). Gram-
positive bacteria stain violet due to the thick layer of peptidoglycan in their cell walls, which 
retains the crystal violet. While Gram-negative bacteria stain red because of the their thinner 
peptidoglycan wall. In the decoloring process the crystal violet will not retain in their cell 
walls.  
Overnight culture(s) of the isolate(s) of interest was prepared before staining (37°C with slow 
shaking, just enough for some motion in the media). The bacterial culture was picked up with 
a Pasteur pipette and placed onto the middle of a glass slide. The media were spread out, but 
not too thin. Thereafter the smear was allowed to air dry completely, and the samples were 
heat fixed to the slide by passing the slide, with smear side up, through the flame rapidly two-
three times. The bacterial smear was then completely covered with the primary stain, Crystal 
violet, and stained for 1 minute. Gently, the dye was washed off with ddH2O. The slide was 
then covered with the mordant, Gram’s iodine, for one minute. Again the slide was gently 
washed with ddH2O. The smear was cautiously rinsed with decolorizer, 96% alcohol, until the 
purple color no longer came off the smear in the alcohol, and then gently washed off with 
ddH2O. The slide was counterstained with safranin for about two minutes, and then gently 
washed with ddH2O. Finally the slide was carefully blotted dry with a paper towel. The slides 






5 EXPERIMENTAL RESULTS 
5.1 Isolation of isolates clinically resistant to mecillinam 
Clinical E. coli isolates with different genetic backgrounds were evolved to become resistant 
to mecillinam. The results from the optimization of the static selection protocol and the 
isolation of resistant mutants are described and displayed below.  
 
5.1.1 Optimization of static selection for mecillinam resistant mutants 
From the static selection of mecillinam resistant mutants, we aimed to isolate mutants with 
MICs above 8 µg/mL, the clinical breakpoint. Initially, a concentration of 32 µg/mL of 
mecillinam in LBA was chosen for the selection (MIC >8 µg/mL). However, this frequently 
resulted in non-resistant mutants (false positives), as determined by MIC-testing (Table 22). 
Several reasons for this were considered, and for pinpointing the problem, some factors were 
investigated: 1) human error; tested by having an observer present during the experiments, 2) 
comparing MH II and LB with multiple concentrations of mecillinam (8, 16 and 32 µg/mL), 
3) retesting a strain that had previously given resistant mutants at 32 µg/mL and 4) rechecking 
drug concentration calculations and comparing two drug stocks prepared by different 
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K56-5 32 M1 
1:10 5 
UD 119 




























a Mecillinam stock prepared by different lab members; M1=member 1, M2=member2. 
b Diluted (1:10) or undiluted (UD) bacterial overnight cultures which were plated on the selective plates with different media.  
c MecR=mecillinam resistant. CFU observed on the respective selective plates. 
	
Undiluted overnight cultures yielded more CFUs compared to diluted overnight cultures 
(1:10). This was shown for both LBA- and MHA plates, although for LBA plates they 
showed more CFUs than for MHA plates. The results showed prominent differences in 
bacterial growth between the two tested media, but no prominent differences were exhibited 
for the different mecillinam stocks. Based on these results, the frequency of resistant mutants 
varies with the type of growth media. 
 
 
5.2 Mutation frequency and MIC of mecillinam resistant mutants 
Mecillinam resistant isolates were generated from ten clinical strains of E. coli, originating 
from the ECO-SENS collection. Three different phenotypes of each strain were isolated, and 
at least one phenotype isolated for each strain was chosen for MIC-testing. Ten of the 15 
mecillinam resistant isolates obtained were selected for further analysis (Appendix A). The 




Table 23: Mutation frequency and MIC-values for mecillinam resistant isolates. The isolated mecillinam resistant 
mutants in bold were the ones selected for further analysis. See Appendix A for the complete results.  
Parental isolate Mutation frequency Isolated mutants MIC (µg/mL) 
  I ≥256 
K56-5 1,44x10-5 II ND 
  III ND 
  I 32 
K56-17 2,04x10-7 II 48 
  III 24 
  I 8 
K56-18 9,54x10-6 II 24 
  III 12 
  I ND 
K56-20 1,33x10-7 II 32 
  III 0,5 
  I 32 
K56-23 9,18x10-6 II ND 
  III ND 
  I 64 
K56-24 3,35x10-7 II ND 
  III ND 
  I 24 
K56-31 1,48x10-6 II ND 
  III ND 
  I ≥256 
K56-66 1,58x10-7 II ND 
  III ND 
  I ≥256 
K56-69 1,02x10-6 II 48 
  III 128 
  I 48 
K56-71 2,35x10-6 II ND 
  III ND 
ND = MIC not determined. 
 
The lowest mutation frequency was for strain K56-80 (7,28x10-8) and the highest was for 
strain K56-30 (6,91x10-5). The highest MIC-values above the clinical breakpoint were for 
strains K56-5, -30, -66 and -69 (≥256 µg/mL), and the lowest was strain K56-18 (12 µg/mL) 
(Table 23).  
All isolates were confirmed by MALDI-TOF as E. coli. The results showed scores over 2,0 





5.3 Collateral sensitivity/cross-resistance networks  
Ten out of 15 strains were selected for further testing and determination of possible collateral 
sensitivity and collateral resistance networks. The antimicrobial concentration resulting in 
90% inhibition of growth (IC90) was determined for the selected isolates for eight 
antimicrobial agents; amoxicillin, chloramphenicol, ciprofloxacin, gentamicin, mecillinam, 
nitrofurantoin, tetracycline and trimethoprim. 
The IC90-values for the mutants were compared to the parental WTs. The results are displayed 
in Table 24 as a heat map, presenting the fold-changes in the IC90-values. The fold changes 
have been color coded according to the description below in the respective table. In this 
project, only 2-fold changes in collateral sensitivity were considered as relevant changes, thus 
only ≥2-fold changes have been assigned color codes. Red tones denote cross-resistance and 
blue tones denote collateral susceptibility. The largest decrease in IC90 between the parental 
WTs and the mutants, showing the highest tendency towards collateral sensitivity, was a 
0,125-fold change in amoxicillin susceptibility for isolates K56-23 and K56-66. Three-fold 
increases in the IC90 values to gentamicin and trimethoprim were observed for single isolates, 
demonstrating cross-resistance.  
The average fold changes across all ten isolates were calculated. On average, our mecllinam 
resistant mutants exhibited the highest tendency to cross-resistance with ciprofloxacin (1,307-
fold change), while the highest tendency for collateral sensitivity was to chloramphenicol 





Table 24: Collateral sensitivity profiles of mecillinam resistant mutants. A heat map displaying the fold changes for 
collateral sensitivity(CS)/cross-resistance(CR) for all ten strains that were compared to the parental WTs, and the average of 
the fold change values (Mecillinam Avg) were calculated for each antimicrobial. The blue coloring denotes CS, red coloring 
denotes CR and white coloring denotes 1-fold change, alias no fold changes, in CS/CR. For abbreviations see Table 11. 
Strain AMX CHL CIP GEN MEC NIT TET TMP 
K56-5 2 1 1 3 21 1 1 2 
K56-17 0,5 0,333 0,75 0,5 21 0,75 1 0,5 
K56-18 1 0,5 1 0,375 21 0,667 1 0,667 
K56-20 0,5 0,5 1,5 0,5 21 1,5 1 0,658 
K56-23 0,125 0,667 1,95 0,376 507 0,5 1,5 3 
K56-24 1 0,75 2 1 24 1 1,5 0,752 
K56-31 1 0,75 1,333 1 21 1 1 1 
K56-66 0,125 0,25 0,75 0,75 64 0,667 0,5 1 
K56-69 1 1 2,04 0,665 128 1,5 1 1,5 
K56-71 1 0,667 0,75 0,75 85 1 1 1 
Mecillinam Avg. 0,825 0,642 1,307 0,892 91,3 0,958 1,050 1,208 
 
      
 
            
0,125 0,25 0,5 1 2 4 8 16 32 64 
 
In order to graph the average susceptibility changes on the same axis it was necessary to log 
transform the fold changes as shown in Figure 11, the 95% confidence interval (CI 95%) is 
also shown. This figure allows for more general description of the collateral sensitivity profile 
in the collection of ten isolates. 
 
Figure 11: Distribution of collateral sensitivity(CS)/cross-resistance(CR). Showing the average fold change for 
mecillinam resistant mutants to eight different antimicrobial agents with CI 95%. Blue coloring denotes CS, and red coloring 




In general, the mecillinam resistant mutants frequently displayed low-level collateral 
sensitivity (0,983-fold change in net result). During the experiments, we observed a couple of 
mecillinam resistant mutants from K56-23 and K56-24 that made small colonies and 




5.4 Optimization of PCR 
In this project, we wanted to amplify and sequence certain of genes that are involved in 
mecillinam resistance. Initially, we struggled with contamination of the PCR reactions, which 
was evident by having bands in the negative control (mastermix and water). Finally, after 
switching to aerosol resistant tips and exchanging all buffers and nuclease-free water, the 
contamination was absent. DNA isolations were also repeated to obtain samples without 
possible EtOH and protein contaminants, which interfered with the PCR reactions. 
Several of the primers that were ordered or designed for this study showed unspecific binding, 
which caused multiple bands on the agarose gel, and others gave no amplified product at the 
annealing temperature indicated by the calculations. Gradient PCRs (50-60°C) were 
performed in an attempt to optimize the running conditions. An example of a gel from a 
gradient PCR setup is shown in Figure 12. Furthermore, problems with contaminated DNA 
templates were encountered.  
 
Figure 12: Gradient PCR for mrdA1. The whole gradient spanning from 50°C to 60°C. The area marked in red gave an 





The results from the gradient PCR performed for mrdA1 (wells from 1-12 contain samples of 
negative controls of ddH2O and wells from 13-24 contain samples of WT K56-24) showed 
amplified PCR products (bands) at approximately 50- and 59°C. Due two several bands at 
approximately 59°C, marked in red, a new annealing temperature at 59°C for mrdA1 was 
chosen. 
Finally, investigations for potential mutations were focused on mrdA gene, as it is the 
mecillinam drug target, due to time constraints. To amplify the whole gene, three primer sets 
were required. Two of these (mrdA1 and mrdA3) gave several bands even with optimization 
of the annealing temperature, and the amplicons were in the end primarily isolated from the 
agarose gel to obtain templates for sequencing. An example of such gel is shown in Figure 13. 
 
Figure 13: Multiple bands of PCR-products. Displayed is PCR with mrdA1 at 50°C for K56-23 WT (well 2), mutant (well 
3) and negative control with ddH2O (well 4).  
 
 
5.5 Genetic mutations in the mrdA gene 
To identify potential mutations in the mrdA gene, which may confer mecillinam resistance, 
the PCR-products were sequenced. The isolates with good quality DNA sequences were 
aligned to the E. coli MG1655 genome. The respective isolates were mutants of strain K56-5, 
-18, -23 and -66. Only parts of the mrdA gene were compared. The results are displayed in 




Table 25: The different mutations detected for mecillinam resistant isolates compared to E. coli MG1655. The arrow 
indicates what kind of alteration in the amino acid sequence the mutation caused.  
Detected mutations Amino acid alteration  Detected mutations Amino acid alteration 
CAG498CAA Gln à Gln GGC427GGT Gly à Gly 
CCT481CCG Pro à Pro CCT430CCA Pro à Pro 
TAC533TAT Tyr à Tyr CAG436CAA Gln à Gln 
GCT535GCC Ala à Ala ACA459ACG Thr à Thr 
GGT594GGC Gly à Gly CCA462CCT Pro à Pro 
GGT595GGC Gly à Gly TTG483TTA Leu à Leu 
ACA602ACG Thr à Thr   




Figure 14: DNA alignment of the mutant and its parental WT. The red marked area is an example of a point mutations 
observed in the mecillinam resistant mutant (K56-66) compared to MG1655 of E. coli.  
 
The results showed 13 synonymous point mutations, in which the mutation in the respective 








5.6 Chain growth effect of E. coli cells 
All parental WT isolates and their mecillinam resistant mutants were investigated under a 
light microscope after Gram staining.  
In general, observations showed that mutants were more spherical and smaller in size 
compared to their parental WTs. There were some color intensity differences as well, which 
in two out of ten cases the mutants showed higher color intensity than their parental WTs 
(isolates of K56-18 and -23). Observations through the light microscope also showed five out 
of ten mutants (isolates of K56-5, -18, -20, -24 and -69) grew more in pairs or slightly more in 
chains than their parental WTs. However, in general, the results showed no prominent 
differences between the mutants and their parental WTs (Figure 15). 
 
	
Figure 15: Cells of clinical isolates of E. coli. Comparison of mecillinam resistant isolate (A) of strain K56-5 and its 






The successful discovery of antimicrobial agents is unfortunately comprised by the inevitable 
emergence of AMR (1, 4). Since the first cases of AMR in the 1940s, it has been threatening 
the success, and modern management of infectious diseases (15), and worse leading to 
widespread fatalities and economic disruption globally (14). To tackle the bacterial 
development of AMR mechanisms novel treatment strategies are required to ensure effective 
treatment of infections. Translating collateral sensitivity networks into treatment-guidelines 
may retard the evolution of antimicrobial resistance by constraining the evolutionary paths 
towards resistance. The main focus in this project has been to expand the knowledge of this 
phenomenon through generating collateral sensitivity/cross-resistance networks. Hence may 
lay the scientific foundation to establish a novel treatment strategy for UTIs caused by E. coli 
and prevent further resistance development. We approached this by evolving resistant to 
mecillinam, a relevant antimicrobial in UTI treatment, in clinical strains of E. coli from UTIs. 
We further proceeded to explore the collateral sensitivity/cross-resistance networks of the 
resistant isolates and took a closer look at some of the mutants in an attempt to find the 
mechanisms behind our observations.  
 
 
6.1 Collateral sensitivity/cross-resistance networks 
The resulting collateral sensitivity/cross-resistance networks in our study are displayed in heat 
maps and a graph showing the distribution of antimicrobial susceptibilites to various agents. 
In this context, we are not using the terms “collateral sensitivity” and “cross-resistance” from 
a clinical point of view, but rather as changes in the antimicrobial susceptibility that we might 
be able to employ in order to control AMR development. Our results showed that both 
collateral sensitivity and cross-resistance occurred for mecillinam resistant isolates. However, 
a substantial tendency for collateral sensitivity frequently appeared compared to cross-
resistance (0,983-fold change in net result). This is in concurrence with previous unpublished 





In Imamovic et al.’s study, CS drug cycling was demonstrated for various antimicrobial 
agents (38). However, mecillinam was not included in that study. Our results showed that 
across all antimicrobial agents tested the overall average fold change was below 1,0. Though, 
for amoxicillin, chloramphenicol and gentamicin collateral sensitivity was demonstrated for 
four out of ten strains. Hence at this point our data does not support that the collateral 
sensitivity patterns are general enough to employ mecillinam in CS drug cycling. However, 
there are several aspects of the study that should be highlighted. Ten diverse clinical isolates 
of E. coli from the ECO-SENS collection from patients with UTIs were used. Compared to 
previous studies, this is a substantial number of strains, giving a better description of what is 
to be expected on the population level (38, 39). Our IC90 results were very tight, with the two 
replicates giving very similar results in most cases. The statistical power of IC90-assay 
provides high validity and resilience in our data. Additionally, the most interesting finding in 
our results was the rare tendency of cross-resistance observed for mecillinam resistant 
mutants. Thus mecillinam might be a good candidate to be employed as the first drug of 
choice for UTIs. Our findings provide proof of principle for collateral sensitivity, which may 
be an important key to interfere with resistance development. The study also contributes 
scientific evidence to other previous works to which our comparisons show high consistency 
(38, 39). However, these assumptions are based on in vitro results. Thus further investigations 
should be tested in vivo and possibly in clinical trials as well. 
 
 
6.1.1 Comparison to previous works on collateral sensitivity 
Imamovic and Sommer, 2013 
Imamovic and Sommer demonstrated collateral sensitivity in E. coli MG1655 and suggested 
to use these CS-networks to inform drug cycling strategies (38). In their study, tendency of 
collateral sensitivity was frequent, where 17 of the 23 resistant E. coli isolates exhibit 
collateral sensitivity to at least one other microbial agent (38). Mecillinam was not included 
among the antimicrobial agents to which the bacterial isolates were evolved to become 
resistance to. Hence our comparison of the results is based on the data from the same 




Similar to this study, a heat map was used to display the collateral sensitivity profiles of 
antimicrobial resistant E. coli strains. According to our results, mecillinam resistant mutants 
displayed collateral sensitivity towards amoxicillin and chloramphenicol contrasting to their 
study where cross-resistance was more frequently observed (up to 32-fold change). Their data 
also show more cross-resistance interactions towards tetracycline (2-fold change increase for 
all β-lactam-resistant isolates except for one), and towards nitrofurantoin it shows both 
collateral sensitivity and cross-resistance to a similar extend, while our results exhibited 
almost no change in the antimicrobial susceptibility towards both agents. Nitrofurantoin 
affects several targets in the bacterial cell wall, which may partly explain the variation 
observed for collateral sensitivity and cross-resistance. Resemblances seen in both studies are 
towards ciprofloxacin and trimethoprim to which prominent cross-resistance is observed for 
all β-lactam-resistant isolates (up to 8-fold change increase).  
In general, we observed more collateral sensitivity for mecillinam-/β-lactam-resistant isolates 
in our study, especially towards chloramphenicol and amoxicillin in contrast to their study. 
The limited number of clinical strains they were using may cause the dissimilarities as 
displayed in our comparison.  
MG1655 strain of E. coli was selected for resistance to 23 different antimicrobial agents. Two 
clinical isolates were selected for resistance to a subset of eight of the original 23 
antimicrobials. Thus the resistant isolates have a limited variation in their genetic background.  
We used ten clinical isolates of E. coli, giving us more solid data to test the generality of the 
networks on the population level. As demonstrated in our experiments, both collateral 
sensitivity and cross-resistance can occur within one antimicrobial agent tested across various 
strains. Thus it is important to include isolates with various genetic backgrounds to observe if 
collateral sensitivity networks also exist on the population level.  
Lázár et al., 2013 
Lázár and co-workers also aimed to determine how frequently collateral sensitivity occurred 
as well as the underlying mechanisms (39). They noticed populations exposed to the same 
antimicrobial agent showed very similar antimicrobial susceptibility patterns. The results 
were charted to a network of collateral sensitivity interactions between several antimicrobial 
agents, which were grouped according to their mode of action(s). Our comparison is based on 
the data of cell wall-inhibitors; the same antimicrobial class as mecillinam (mecillinam and 




Similarities seen in both studies are for instance the same tendency of collateral sensitivity 
towards gentamicin and nitrofurantoin when strains of E. coli develop resistance to 
antimicrobials with cell wall as their drug target. Based on their results, several major patterns 
were observed. One of them was that the distribution of interactions was strongly influenced 
by the mode of action(s) of the antimicrobial agents. The results from both studies may not be 
comparable since mecillinam was excluded in their study. However, based on this respective 
pattern, mecillinam resistant mutants might have exhibited the same collateral sensitivity and 
cross-resistance interactions as the other mutants with adaption to cell wall-inhibitor agents.  
The authors reported no collateral sensitivity interactions towards chloramphenicol. The 
results presented here suggest that in a broader collection of clinical isolates, more CS-
networks exist. In their study, the isolates were from the same one ancestral clone that was 
propagated to ten independent populations. As discussed earlier, this might not be 
representative on the population level. Furthermore, they were using another method to 
estimate collateral sensitivity. The sensitivity of each resistant isolate was tested against 
different antimicrobial agents and the growth in the liquid cultures was measured at half-
maximal effective concentration (EC50). EC50 and IC90 are both units that measure the drug’s 
potency to the isolate of interest. Though, different units of measurement might cause the 
dissimilarities in our comparisons.  
Lázár et al. observed that collateral sensitivity to other antimicrobial classes is uncommon for 
most of the classes. However, as same as for Imamovic and Sommer, they observed several 
major patterns in their study (one of them already mentioned above), including exhibition of 
high tendency of collateral sensitivity towards other classes when strains of E. coli develop 
resistance to aminoglycosides (38, 39).  
MicroPop, 2015 
In general, our comparison with MicroPop’s preliminary data displays high consistency 





Figure 16: Distribution of collateral sensitivity/cross-resistance. Showing the average log MIC for mecillinam resistant 
mutants with CI 95%, generated by MicroPop (to the left) and our project (to the right). Blue coloring indicates collateral 
sensitivity, and red coloring indicates cross-resistance. Permission obtained from: MicroPop research group at UiT – The 
Arctic University of Norway in Tromsø, unpublished preliminary data. 
 
The same tendency of collateral sensitivity/cross-resistance networks was observed for both 
studies. As described earlier, MicroPop performed gradient strip diffusion assays for MIC 
testing to investigate the antimicrobial susceptibility patterns, while we used IC90-assays. 
Despite using different methods, similar results for collateral sensitivity/cross-resistance for 
both studies provided comparable data even though only one replicate was performed in their 
study. In their work, mecillinam resistant mutants displayed collateral sensitivity towards 
nitrofurantoin, gentamicin, amoxicillin and chloramphenicol. In our study, mecillinam 
resistant mutants revealed prominently stronger collateral sensitivity towards gentamicin. 




Tetracycline was the agent that showed contradictory results. In our study, mecillinam 
resistant mutants showed weak cross-resistance interactions towards tetracycline. While the 
opposite is demonstrated for MicroPop’s study showing clear collateral sensitivity 
interactions. However, the CI 95%-values between the studies do overlap. CI is used to 
describe the amount of uncertainty associated with a sample method that includes an 
unknown population parameter. In other words, the calculated CI 95% shows a range of 
values where there is a likelihood of 95% that the next replicate performed will fall within the 
respective interval (103). Thus when the CI 95%-values for both studies include “0” on the x-
axis, the “next” mecillinam resistant isolate tested against tetracycline might show no change. 
Hence the differences for both studies are not considered significant. Ongoing replicate 
experiments will improve the statistical power in these analyses. 
 
6.1.2 Different strategies for CS cycling 
As mentioned in the section 1.3.5, the hypothesis behind conventional drug cycling is based 
on the assumption that resistance is accompanied by biological fitness cost, thus leading to 
eradication of resistant bacteria when absence of the selective pressure imposed by drug 
treatment (32, 43). However, bypass mechanisms may allow genetic adaption and 
maintenance of the resistance phenotype despite exclusion of antimicrobial agents 
deployment (32, 37). Furthermore, in clinical settings, eradication of all resistance pathogens 
is required so that reversibility can occur, even though the rate of reversibility is expected to 
be slow at the community level (32).  
Several studies have suggested CS cycling as a novel treatment strategy, which constrains 
evolutionary paths to AMR (38, 40).  
A study proposed a different approach to the conventional drug cycling (38). This was based 
on the findings that the development of resistance to one antimicrobial agent might alter the 
antimicrobial susceptibility profile for that respective bacterial cell. Hence resulting in 
collateral sensitivity and cross-resistance toward other antimicrobials. They called this novel 
treatment strategy for CS drug cycling (section 1.4) (38). However, in their experiments, not 
all antimicrobials could be used in two-drug cycles because use of agents with cross-
resistance will provide a selective advantage to the resistant strain over the WT leading to 




profiles could be included in the cycle leading to a change in antimicrobial susceptibility 
toward collateral sensitivity. However, this means that deployment of four to five drugs in one 
CS drug cycle would be required, making treatment more complicated. Additional, this 
strategy is dependent on complete eradication of all resistant strains, which may be 
challenging in real-life settings due to unknown evolutionary stability of collateral 
sensitivity/cross-resistance and other factors. 
Another study by Gonzales and co-workers suggests a combination therapy of three different 
β-lactams, all targeting cell wall synthesis (40). This synergistic, collateral sensitive β-lactam 
combination uses elements from three strategies; targeting multiple nodes (connection points) 
in the same cellular system, synergistic effect and collateral sensitivity. This combination 
therapy was suggested to combat methicillin-resistant Staphylococcus aureus (MRSA), a 
multidrug-resistant pathogen. Nevertheless, in their results, high resistance to one of the two 
β-lactams slightly reduces effectiveness of the synergistic, collateral sensitive β-lactam 
combination. Furthermore, HGT was not taken into account in their analysis, which can break 
the synergetic relationship between the β-lactams.  
 
6.1.3 CS cycling versus other antimicrobial treatment strategies 
A promising treatment strategy that may improve pathogen eradication and curb the evolution 
and spread of AMR, is combination therapy. As mentioned above, combination therapy has 
shown its success by taking advantage of synergistic effects of some drug combinations 
(section 1.3.2) (25). However, toxicity has been observed and the issue on whether 
combination therapy reduces mortality in infections with Gram-negative bacteria has been 
brought to light in a meta-analysis (26). According to the analysis, adverse effects are more 
common for patients receiving combination therapy. They also suggest that the survival 
benefit of combination therapy may be none. Moreover, other potential disadvantages 
including increased financial cost and increase in resistance prevalence associated with 
combination therapy. Hence collateral sensitivity cycling may be a more favorable solution to 
the rapidly growing crisis in AMR development. Other treatment strategy includes 





6.1.4 Potential impacts and challenges of CS/CR in clinical settings 
Mecillinam is primarily used in Northen Europe for treatment of UTIs (60). Furthermore, it is 
not available everywhere (e.g. Canada or the US) or not a drug of choice in the 
recommendations of UTIs treatment (section 1.7.2) (54, 55, 57). For instance, trimethoprim 
and nitrofurantoin are the recommended antimicrobials for treatment of acute lower UTI in 
Scotland (54). 
Our work may contribute to developing novel treatment guidelines for the treatment of 
infectious diseases (UTIs). Based on our results, mecillinam might be a good candidate to be 
employed as the first drug of choice for UTIs. Comparison of the results from the MicroPop 
group and our study has shown a clear tendency for collateral sensitivity for mecillinam 
resistant mutants. And, perhaps even more important, the collateral sensitivity profiles 
indicate that mecillinam resistance gives a fair probability of developing of collateral 
sensitivity and low probability of cross-resistance (Figure 16).  
CS/CR networks could be used as tools to inform the choice of primary and secondary 
therapies to ensure effective treatment options, based on drug cycling. Furthermore, several 
studies have anticipated that collateral sensitivity will contribute to the sustainable use of 
drugs in hospital setting by reducing the rate of resistance evolution (27, 40, 41).  
The results from MicroPop and our study are promising. However, more strains need to be 
explored to verify this. Nonetheless, the results from our study and others are from in vitro 
experiments performed in laboratory settings (38, 40). In Thulin et al.’s paper, their results 
show that the mutation frequency of mecillinam resistant mutants is much higher in vitro than 
in the clinical settings (12). Mutations were found for various resistance-conferring genes for 
mecillinam resistant laboratory-selected mutants and for -clinical isolates. However, one 
remarkable thing was that mutations in the cysB gene were found in all of the clinical isolates. 
Furthermore, mecillinam resistant mutants evolved in laboratory settings had severe fitness 
costs with lower growth rates compared to E. coli MG1655. This tendency has been observed 
in other studies, as well as in ours (34, 80). Thulin et al. implies that only a small subset of the 
mutants found in vitro are fit enough to become fixed in the bladder (12).  
These observations demonstrate the possibility that we might see a different result in real-life 




clinical patients with UTIs. Though our observations might be limited to in vitro settings, the 
mecillinam resistant isolates are clinically relevant.   
Also, detection of pathogen species before choice of antimicrobial is not always possible in a 
clinical setting, such as when a patient is admitted for acute infections. Thus using CS in this 
context may be challenging if the first line drugs of choice is dependent on the bacterial 
species. Moreover, the influence of different factors on collateral sensitivity still remains 
unknown. Such factors are, for instance, acquisition of resistance genes through HGT and 
pathogens with MDR.  
 
6.1.5 Management of various deviations in our results 
The results from our collateral sensitivity/cross-resistance networks were displayed with fold 
changes. We performed two replicates for all twenty isolates, both mutants and WTs (section 
4.5.2). The first replicate was performed with 2-fold dilutions, covering a wide range of MIC-
values, to provide us an indication for in what range the IC90-value will be for the respective 
antimicrobial. The second replicate was performed with 1,5-fold dilutions. The results from 
the second replicate were used for the final interpretation due to its higher resolution. 
Furthermore, the results from both replicates were generally consistent. Regarding the more 
slow growing isolates (the mutants based on K56-23 and-24), which were incubated at 18-, 24 
- and 42 hours, the results from 18 hour incubations were used for the interpretation of the 
overall results. Although with 42 hours we achieved higher density, thus higher accuracy and 
confidence in our data, this caused difficulties for our interpretation due to the ATCC-values 
occasionally being out of range after 42 hours and the incubation time not being standardized. 
However, measurements from the various time points showed high similarities suggesting the 
antimicrobial potency was still the same.  
For the replicates to which the values of the ATCC control and K56-44 resistant isolates 
(internal quality control strains) were out of range, another replicate was performed. In our 
final results, ATCC- (for trimethoprim) and K56-44 resistant isolates (for nitrofurantoin) were 
slightly out of range once (Appendix C). We decided to accept the deviation of K56-44 resistant 
isolate since the range can vary for mutants, additionally that occurred in our first replicate (2-
fold change which MIC-value achieved was 4 µg/mL while the range was 6-24 µg/mL). The 




two more replicates were performed for the concerning strains (K56-20 and K56-24). 
However, we continuously got MIC 0,38 µg/mL which equaled to a 1,5-fold lower than 
expected. This may be due to the bacteriostatic effect of trimethoprim, which caused 
difficulties for the range of the ATCC. Furthermore, the range of ATCC-values defined by 
EUCAST are based on standard microbroth dilution testing hence may cause the deviation 
(this matter will be discussed in the next section, 6.1.6). 
Despite these challenges, these defined values were still used in our study due to the lack of 
equally well-established values for IC90-assays. Therefore, in order to achieve a MIC-value 
for ATCC to be in range, the IC90-values calculated for the respective isolates were adjusted 
1,5-fold higher. E.g. initially, the WT of strain K56-20 got MIC 0,25 µg/mL which was 
adjusted to MIC 0,38 µg/mL.  
 
6.1.6 IC90-assessment vs. MIC-testing 
Micro broth dilution with IC90-assessment was chosen for the collateral sensitivity profiling. 
Although IC90-assessment is more time-consuming, there are many advantages regarding this 
method. For instance it is more cost-effective in which the consumables are cheaper compared 
to MIC-testing using the gradient strip method. However, the main reason for why micro 
broth dilution is the preferred method for us is due to the reproducibility. Thus providing us 
high validity and resilience in our results. We also compared our results from the IC90-
assessment with earlier MIC-testing results, which showed high consistency. Furthermore, 
reproducibility of MIC-testing has shown to be challenging, particularly for mecillinam. 
Determination of 100% inhibition zone of bacterial growth was difficult, since spontaneous 
mutants frequently appear. Also, the interpretations were done visually which may affect the 
results due to inter-variability of different interpreters. This manually readings were not a 
problem for IC90-assays since the reads were done automatically with a plate reader. 
Results from AST for mecillinam have shown to be difficult to reproduce in general (section 
1.8) (58). This is due to the high frequency of spontaneous mutations for mecillinam resistant 
isolates (80). The high mutation rate may be explained by in either of two ways; there are one 
or a few genes with high spontaneous mutation frequency, or there are many genes with a 
normal/low spontaneous mutation frequency (80). As mentioned earlier, the frequency of 




for mutations that result in mecillinam resistance (Table 1) (12). Thus these isolates can easily 
be mutated further and make the IC90-assay/MIC-test interpreted level to be artificially high. 
 
 
6.2 Mecillinam resistance-encoding genes 
The second aim in our study was to investigate the underlying mechanisms of the reciprocal 
collateral sensitivity between antimicrobials agents. We approached this by investigating the 
potential mutations in mecillinam resistance-conferring genes. By exploring the resistant 
mechanism, we might find some answers in the underlying mechanisms of collateral 
sensitivity. Potential mutations in the mrdA gene were identified through PCR and DNA 
sequencing. DNA alignments of four mecillinam mutants (K56-5, -18, -23, and -66) were 
compared to the E. coli MG1655 genome. The results displayed 13 synonymous point 
mutations, meaning these point mutations leads to no alteration in the amino acid sequence. 
Thus there are no potential mutations in the respective amplicons that may confer resistance 
and alter the bacterial phenotype. However, our comparison was not optimal. Only part of the 
mrdA gene was compared and the genome of the parental WTs was not the reference genome. 
mrdA gene is one of the known genes that confer mecillinam resistance and shows high 
frequency of mutations in mecillinam resistant mutants (12, 68, 80). Based on our results, we 
can not conclude on the mechanism of the mecillinam resistance, and hence not the 
mechanism of collateral sensitivity observed.  
 
6.2.1 Challenges concerning PCR 
Initially, several genes were chosen for close scrutiny for potential mutations in the genomes 
of mecillinam resistant isolates (1.7.2). However, we experienced challenges regarding PCR, 
additional to the time limitation, which lead to the decision to focus on the mrdA gene only. 
Three primer sets were designed to cover the whole mrdA gene and DNA sequencing was 
supposed to be performed for the entire gene. However, we experienced various difficulties 
during our attempts to amplify the wanted sequence of the gene with PCR. Originally, an 
annealing temperature at 58°C was chosen for all three primer sets after analyzing the primers 




Alignment Search Tool (BLAST) and the OligoAnalyzer 3.1 software. The purpose was to 
detect whether the primer binding to the DNA was specific enough and to find the optimal 
annealing temperature for them respectively. 
The results from agarose gel electrophoresis frequently showed either no amplifications or 
multiple bands with the chosen annealing temperatures. Gradient PCR with 50-60°C were 
therefore performed for mrdA1- and mrdA3-primer sets, which gave us a specific band at 
59°C (for mrdA1) and 50°C (for mrdA3). 
Multiple bands still occurred after performing the agarose gel electrophoresis for mrdA2- and 
mrdA3 amplicons. These bands may be caused by unspecific binding of the primers to the 
genome of E. coli. To investigate this issue, analysis of all three primer sets were done 
through BLAST again to observe whether the primers bind to other microorganisms with 
higher matches than E. coli. The results for all three primer sets showed 100% match for the 
whole sequence of the primers (all 20 nucleotides) only for PBP 2 in E. coli. However, other 
binding-sites in the E. coli genome with partial similarity to the primers may have caused 
unspecific bands.  
Based on the gradient PCRs we adjusted the annealing temperature for the mrdA1 and mrdA3 
primer sets. Time limitation restricted us from further exploring the optimal running 
conditions for these PCRs. Other parts of the running conditions we could have adjusted 
would be to optimize enzyme concentration, lengthen extension time or increase cycle 
number (105). Designing of new primers could also be an option. 
 
 
6.3 Frequency of resistant mutants is depending on type of growth media 
To streamline the protocol of static selection of mecillinam resistant mutants to others used in 
the lab, LBA was exchanged with MHA. According to EUCAST, MH II using for MHA is 
the recommended medium for supplementation of antimicrobial agents (106). This is due to 
its defined contents of cation (calcium and magnesium ions) and thymidine, which are known 





The results from the change of medium demonstrated that the two different growth media 
showed a clear difference in mutation frequency and the number of true resistant mutants 
(Table 22). Moreover a decrease in mecillinam concentration in MHA gave a clear increase in 
the mutation frequency. Based on these results, a concentration of 16 µg/mL mecillinam in 
MHA was chosen for the static selection of mecillinam resistant mutants. 
 
 
6.4 Patterns of cell growth for mecillinam resistant mutants  
Studies have shown that mecillinam resistant mutants are more spherical in shape as a 
consequence of PBP 2 inhibition (11, 12) and also have slower growth rate (34). The current 
thinking is that these phenomena and observations may lead and be due to the chain growth 
effect of the cells. According to our results from Gram staining experiment, there were no 
great differences between mecillinam mutants and their parental strains regarding the chain 
growth of the cells. Due to these findings we presume that the incomplete septation during 
cell division may not lead to chain growth effect. The slower growth of the mutants might be 
due to other fitness costs in the cell function. However, for our mecillinam resistant mutants 
the resistant mechanism is still unknown. Therefore further investigations are required to 
know if these phenomena have an association to the chain growth effect. 
 
 
6.5 Strengths and limitations in the project 
In our project, we included ten clinical E. coli isolates providing us strains with different 
genetic background, which increased our ability to generalize on the population level. 
Furthermore, the eight antimicrobial agents employed in our experiments have high clinical 
relevance since they are frequently used in treatment of UTIs. They also belong to distinct 
chemical classes and have different mode of actions (Table 11). 
Nonetheless, our project has only focused on a single species, meaning our understanding on 
the bacterial evolution globally remains unknown. The medium chosen for bacterial growth 




in living organisms. For instance in a clinical setting, we will probably get a urine sample 
from a patient which can vary in its constituents, e.g. level of proteins, hormones and 
metabolites. Also the anamnesis to a patient and whether the patient is using medicals are 
important factors to take into account. Furthermore, the immune system to a host plays a 
crucial part of the medical response, reflecting the state of health to a host. 
 
6.5.1 Improvements 
To see how conserved collateral sensitivity is across different species, various types of 
pathogens causing UTIs may also be included in our project. Also, in order to create a 
laboratory setting more biologically similar to a clinical setting, we could use urine as 
medium instead.  
Regarding PCR, it has been challenging to investigate the locations of the potential mutations 
in the mrdA gene that may confer resistance. PCR is generally sufficient as a method to 
identify potential mutations in a resistance-encoding gene. However, besides being a relative 
large gene (1902 bp), it is also a housekeeping gene (which the bacteria require for the 
maintenance of basic cellular functions). Thus mrdA gene is relatively conserved (68, 107). 
Hence on the population level the bacteria may allow low degree of mutations in the gene. A 
better way to investigate potential mutations is to perform WGS for all 20 clinical isolates of 
E. coli. Simultaneously, we can also search for mutations in other regions when knowing that 
there are at least 38 genes involved in mecillinam resistance (12). This is of course more 
costly and time-consuming, not to mention the knowledge we have to attain within 
bioinformatics for comparison of the amino acid variability. With WGS we have the 
opportunity to do DNA alignment for all known mecillinam resistance-encoding genes and 
accomplish more information about the mutational patterns. Ideally, we should also use the 
parental WTs as the reference genome for the DNA alignment regarding the differences in the 
genetic backgrounds for the clinical strains. This will provide us a more valid result.  
Finally, to increase the probability for finding mutations in the genome, genes with same 
functions could be included e.g. mrdA and mrdB genes (68). This is based on the assumption 
that mutations in one gene may also cause mutations in another gene with the same cellular 
functions. Furthermore, other resistant-conferring genes, which have shown high frequency of 




genes are thrS-, aspS- and gtlX genes, encoding threonyl-tRNA synthetase, aspartate tRNA 
ligase and glutamyl-tRNA-synthetase respectively (12). Nonetheless, according to Thulin et 
al.’s paper, mutations in the cysB gene are remarkably common for all clinical resistant 
isolates of E. coli. The CysB protein, encoded by the cysB gene, is the main positive regulator 
of cysteine biosynthesis. The mechanism behind this gene conferring resistance still remains 
unclear, but some suggest that this is partly due to the increased intracellular levels of ppGpp 







We suggest mecillinam could be a potential candidate for the first drug of choice in treatment 
of UTIs caused by E. coli. This suggestion is based on our findings as well as previous 
unpublished results from our group (MicroPop at UiT – The Arctic University of Norway in 
Tromsø) showing that collateral sensitivity interaction with other antimicrobial agents 
frequently occurs for mecillinam resistant mutants. Most strikingly, cross-resistance is rarely 
seen for mecillinam resistant mutants. We believe that these collateral sensitivity/cross-
resistance interactions will occur on the population level as well. Unfortunately, the 
underlying mechanism(s) of the reciprocal collateral sensitivity between antimicrobial agents 
still remains unclear.  
Furthermore, we insinuate reduction in growth rate for mecillinam resistant mutants found in 
laboratory selections may have an impact in clinical settings. Thulin et al. have also indicated 
this, based on reduced fitness cost, these mutants may have difficulties to maintain stable in a 





8 FUTURE ASPECTS 
Since the introduction by the first pioneers, much progress in our knowledge of collateral 
sensitivity has been explored. However, there are several knowledge gaps that should be 
studied further concerning collateral sensitivity/cross-resistance patterns (CS/CR).  
Ø How conserved are the CS/CR patterns; regarding the diversity on species level, and 
even globally. Furthermore, will MDR lead to alteration in the CS/CR patterns?  
Ø What is the underlying mechanism(s) of collateral sensitivity; so far suggestions of 
different underlying mechanisms and factors may contribute to this matter; such as 
reduced activity of the efflux pumps and fitness cost. Although, there are many 
unanswered questions. 
Ø How stable are the CS/CR patterns; will the bacterial evolutionary adaption of 
antimicrobial agents also occur for CS as for CR, and will these patterns remain stable 
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Appendix A: Complete results from static selection of mecillinam resistant mutants. The isolated mecillinam mutants 











MIC (µg/mL) Species 
confirmation 
MALDI-TOF 
K56-5 3,20x107 460 1,44x10-5 I ≥256 X 
     II    
     III    
K56-17 5,40x108 110 2,04x10-7 I 32   
     II 48 X 
     III 24   
K56-18 8,70x107 830    9,54x10-6 I 8   
     II 24 X 
     III 12   
K56-20 4,50x108 60 1,33x10-7 I    
     II 32 X 
     III 0,5   
K56-23 1,46x108 1340 9,18x10-6 I 32 X 
     II    
     III    
K56-24 1,79x108 60 3,35x10-7 I 64 X 
     II    
     III    
K56-25 3,90x108 840 2,15x10-6 I    
     II 24 X 
     III    
K56-30 1,10x107 760 6,91x10-5 I ≥256   
     II    
     III    
K56-31 7,50x108 1110 1,48x10-6 I 24 X 
     II    
     III    
K56-66 5,70x108 90 1,58x10-7 I ≥256 X 
     II  X 
     III    
K56-69 1,66x108 170 1,02x10-6 I ≥256 X 
     II 48 X 
     III 128   
K56-71 2,43x108 570 2,35x10-6 I 48 X 
     II    
     III    
















MIC (µg/mL) Species 
confirmation 
MALDI-TOF 
K56-76 1,20x109 760 6,33x10-7 I 24 X 
     II    
     III    
K56-77 6,00x108 190 3,17x10-7 I 48 X 
     II  X 
     III    
K56-80 4,12x108 30 7,28x10-8 I 48 X 
     II  X 





















A6 1 Escherichia coli 2,439 Escherichia coli 2,317 
A7 1 Escherichia coli 2,322 Escherichia coli 2,306 
A8 1 Escherichia coli 2,341 Escherichia coli 2,335 





Appendix C: IC90-determination. Tested for eight different antimicrobial agents on ten parental WTs and their 



















K56-5 WT 64 µg/mL 8 µg/mL 2 2 2 2 
K56-5 MEC 64 µg/mL 8 µg/mL 4 4 
K56-17 WT 64 µg/mL 8 µg/mL 2 2 0,5 0,5 
K56-17 MEC 64 µg/mL 8 µg/mL 1 1 
K56-18 WT 64 µg/mL 8 µg/mL 2 1,5 1 1 
K56-18 MEC 64 µg/mL 8 µg/mL 2 1,5 
K56-20 WT 64 µg/mL 8 µg/mL 2 2 1 0,5 
K56-20 MEC 64 µg/mL 8 µg/mL 2 1 
K56-23 WT 64 µg/mL 8 µg/mL 4 3 0,25 ≤0,125 
K56-23 MEC 64 µg/mL 8 µg/mL 1 ≤0,375 
K56-24 WT 64 µg/mL 8 µg/mL 2 1,5 1 1 
K56-24 MEC 64 µg/mL 8 µg/mL 2 1,5 
K56-31 WT 64 µg/mL 8 µg/mL 2 3 2 1 
K56-31 MEC 64 µg/mL 8 µg/mL 4 3 
K56-66 WT 64 µg/mL 8 µg/mL 4 4 0,125 0,125 
K56-66 MEC 64 µg/mL 8 µg/mL 0,5 0,5 
K56-69 WT 64 µg/mL 8 µg/mL 8 6 1 1 
K56-69 MEC 64 µg/mL 8 µg/mL 8 6 
K56-71 WT 64 µg/mL 8 µg/mL 4 4 1 1 
K56-71 MEC 64 µg/mL 8 µg/mL 4 4 
ATCC 64 µg/mL 8 µg/mL 8 or 4 6 or 4     
K56-44 MEC 64 µg/mL 8 µg/mL 8 or 4 4 or 3 






















K56-5 WT 32 µg/mL 32 µg/mL 4 3 1 1 
K56-5 MEC 32 µg/mL 32 µg/mL 4 3 
K56-17 WT 32 µg/mL 32 µg/mL 4 6 0,5 0,333 
K56-17 MEC 32 µg/mL 32 µg/mL 2 2 
K56-18 WT 32 µg/mL 32 µg/mL 4 4 1 0,5 
K56-18 MEC 32 µg/mL 32 µg/mL 4 2 
K56-20 WT 32 µg/mL 32 µg/mL 4 4 1 0,5 
K56-20 MEC 32 µg/mL 32 µg/mL 4 2 
K56-23 WT 32 µg/mL 32 µg/mL 8 4 0,5 0,5 
K56-23 MEC 32 µg/mL 32 µg/mL 4 2 
K56-24 WT 32 µg/mL 32 µg/mL 2 2 1 ≤0,75 
K56-24 MEC 32 µg/mL 32 µg/mL 2 ≤1,5 
K56-31 WT 32 µg/mL 32 µg/mL 4 8 2 0,75 
K56-31 MEC 32 µg/mL 32 µg/mL 8 6 
K56-66 WT 32 µg/mL 32 µg/mL 8 6 1 0,25 
K56-66 MEC 32 µg/mL 32 µg/mL 8 ≤1,5 
K56-69 WT 32 µg/mL 32 µg/mL 8 12 1 1 
K56-69 MEC 32 µg/mL 32 µg/mL 8 12 
K56-71 WT 32 µg/mL 32 µg/mL 8 6 1 0,667 
K56-71 MEC 32 µg/mL 32 µg/mL 8 4 
ATCC 32 µg/mL 32 µg/mL 4 3 or 4     

























K56-5 WT 2 µg/mL 0,125 µg/mL 0,008 0,012 2 1 
K56-5 MEC 2 µg/mL 0,125 µg/mL 0,016 0,012 
K56-17 WT 2 µg/mL 0,125 µg/mL 0,016 0,016 0,5 0,75 
K56-17 MEC 2 µg/mL 0,125 µg/mL 0,008 0,012 
K56-18 WT 2 µg/mL 0,125 µg/mL 0,008 0,012 2 1 
K56-18 MEC 2 µg/mL 0,125 µg/mL 0,016 0,012 
K56-20 WT 2 µg/mL 0,125 µg/mL 0,008 0,008 1 1,5 
K56-20 MEC 2 µg/mL 0,125 µg/mL 0,008 0,012 
K56-23 WT 2 µg/mL 0,125 µg/mL 0,016 0,012 1,98 2,58 
K56-23 MEC 2 µg/mL 0,125 µg/mL 0,031 0,031 
K56-24 WT 2 µg/mL 0,125 µg/mL 0,008 ≤0,006 1 ≥2 
K56-24 MEC 2 µg/mL 0,125 µg/mL 0,008 0,012 
K56-31 WT 2 µg/mL 0,125 µg/mL 0,008 0,012 2 1,333 
K56-31 MEC 2 µg/mL 0,125 µg/mL 0,016 0,016 
K56-66 WT 2 µg/mL 0,125 µg/mL 0,016 0,016 1 0,75 
K56-66 MEC 2 µg/mL 0,125 µg/mL 0,016 0,012 
K56-69 WT 2 µg/mL 0,125 µg/mL 0,016 0,023 2 2,04 
K56-69 MEC 2 µg/mL 0,125 µg/mL 0,031 0,047 
K56-71 WT 2 µg/mL 0,125 µg/mL 0,008 0,016 2 0,75 
K56-71 MEC 2 µg/mL 0,125 µg/mL 0,016 0,012 
ATCC 2 µg/mL 0,125 µg/mL 0,008 0,008     























K56-5 WT 32 µg/mL 1 µg/mL 0,125 0,125 2 3 
K56-5 MEC 32 µg/mL 1 µg/mL 0,25 0,375 
K56-17 WT 32 µg/mL 1 µg/mL 0,125 0,188 1 0,5 
K56-17 MEC 32 µg/mL 1 µg/mL  0,125 0,094 
K56-18 WT 32 µg/mL 1 µg/mL 0,5 0,25 0,25 0,375 
K56-18 MEC 32 µg/mL 1 µg/mL 0,125 0,094 
K56-20 WT 32 µg/mL 1 µg/mL 0,25 0,25 0,5 0,5 
K56-20 MEC 32 µg/mL 1 µg/mL 0,125 0,125 
K56-23 WT 32 µg/mL 1 µg/mL 1 0,375 0,25 ≤0,125 
K56-23 MEC 32 µg/mL 1 µg/mL 0,25 ≤0,047 
K56-24 WT 32 µg/mL 1 µg/mL 0,5 0,188 0,5 1 
K56-24 MEC 32 µg/mL 1 µg/mL 0,25 0,188 
K56-31 WT 32 µg/mL 1 µg/mL 0,25 0,25 1 1 
K56-31 MEC 32 µg/mL 1 µg/mL 0,25 0,25 
K56-66 WT 32 µg/mL 1 µg/mL 0,5 0,25 0,5 0,75 
K56-66 MEC 32 µg/mL 1 µg/mL 0,25 0,188 
K56-69 WT 32 µg/mL 1 µg/mL 0,25 0,188 0,5 0,665 
K56-69 MEC 32 µg/mL 1 µg/mL 0,125 0,125 
K56-71 WT 32 µg/mL 1 µg/mL 0,25 0,25 2 0,75 
K56-71 MEC 32 µg/mL 1 µg/mL 0,5 0,188 
ATCC 32 µg/mL 1 µg/mL 0,25 or 0,5 0,25 or 0,75      
























K56-5 WT 4 µg/mL 4 µg/mL 
4 µg/mL 
0,125 ≤0,188 ≥32 ≥21 
K56-5 MEC 4 µg/mL ≥4 ≥4 
K56-17 WT 4 µg/mL 4 µg/mL 
4 µg/mL 
0,125 ≤0,188 ≥32 ≥21 
K56-17 MEC 4 µg/mL ≥4 ≥4 
K56-18 WT 4 µg/mL 4 µg/mL 
4 µg/mL 
0,25 ≤0,188 ≥16 ≥21 
K56-18 MEC 4 µg/mL ≥4 ≥4 
K56-20 WT 4 µg/mL 4 µg/mL 
4 µg/mL 
0,125 ≤0,188 32 21 
K56-20 MEC 4 µg/mL 4 4 
K56-23 WT 4 µg/mL 1 µg/mL 
32 µg/mL 
0,125 0,063 ≥32 ≥507 
K56-23 MEC 4 µg/mL ≥4 ≥32 
K56-24 WT 4 µg/mL 1 µg/mL 
32 µg/mL 
0,063 0,063 ≥64 ≥24 
K56-24 MEC 4 µg/mL ≥4 24 
K56-31 WT 4 µg/mL 4 µg/mL 
4 µg/mL 
0,125 ≤0,188 ≥32 ≥21 
K56-31 MEC 4 µg/mL ≥4 ≥4 
K56-66 WT 4 µg/mL 1 µg/mL 
16 µg/mL 
0,125 0,094 16 ≥64 
K56-66 MEC 4 µg/mL 2 2 
K56-69 WT 4 µg/mL 1 µg/mL 
16 µg/mL 
0,25 0,125 ≥16 ≥128 
K56-69 MEC 4 µg/mL ≥4 ≥16 
K56-71 WT 4 µg/mL 1 µg/mL 
16 µg/mL 
0,25 0,188 ≥16 85 
K56-71 MEC 4 µg/mL ≥4 16 
ATCC 4 µg/mL 1 µg/mL 
16 µg/mL 
0,125 0,094     























K56-5 WT 64 µg/mL 32 µg/mL 8 6 1 1 
K56-5 MEC 64 µg/mL 32 µg/mL 8 6 
K56-17 WT 64 µg/mL 32 µg/mL 8 8 1 0,75 
K56-17 MEC 64 µg/mL 32 µg/mL 8 6 
K56-18 WT 64 µg/mL 32 µg/mL 16 12 0,5 0,667 
K56-18 MEC 64 µg/mL 32 µg/mL 8 8 
K56-20 WT 64 µg/mL 32 µg/mL 4 4 2 1,5 
K56-20 MEC 64 µg/mL 32 µg/mL 8 6 
K56-23 WT 64 µg/mL 32 µg/mL 8 8 0,5 0,375 
K56-23 MEC 64 µg/mL 32 µg/mL 4 3 
K56-24 WT 64 µg/mL 32 µg/mL 8 3 1 1 
K56-24 MEC 64 µg/mL 32 µg/mL 8 3 
K56-31 WT 64 µg/mL 32 µg/mL 16 12 1 1 
K56-31 MEC 64 µg/mL 32 µg/mL 16 12 
K56-66 WT 64 µg/mL 32 µg/mL 8 6 1 0,667 
K56-66 MEC 64 µg/mL 32 µg/mL 8 4 
K56-69 WT 64 µg/mL 32 µg/mL 16 8 1 1,5 
K56-69 MEC 64 µg/mL 32 µg/mL 16 12 
K56-71 WT 64 µg/mL 32 µg/mL 4 8 1 1 
K56-71 MEC 64 µg/mL 32 µg/mL 4 8 
ATCC 64 µg/mL 32 µg/mL 4 or 8 4 or 8     
























K56-5 WT 16 µg/mL 4 µg/mL 1 0,75 1 1 
K56-5 MEC 16 µg/mL 4 µg/mL 1 0,75 
K56-17 WT 16 µg/mL 4 µg/mL 1 0,75 1 1 
K56-17 MEC 16 µg/mL 4 µg/mL 1 0,75 
K56-18 WT 16 µg/mL 4 µg/mL 1 0,75 1 1 
K56-18 MEC 16 µg/mL 4 µg/mL 1 0,75 
K56-20 WT 16 µg/mL 4 µg/mL 1 0,75 2 1 
K56-20 MEC 16 µg/mL 4 µg/mL 2 0,75 
K56-23 WT 16 µg/mL 4 µg/mL 1 0,75 2 1,333 
K56-23 MEC 16 µg/mL 4 µg/mL 2 1 
K56-24 WT 16 µg/mL 4 µg/mL 0,5 0,25 1 1,5 
K56-24 MEC 16 µg/mL 4 µg/mL 0,5 0,375 
K56-31 WT 16 µg/mL 4 µg/mL 1 0,75 2 1 
K56-31 MEC 16 µg/mL 4 µg/mL 2 0,75 
K56-66 WT 16 µg/mL 4 µg/mL 2 1 0,25 0,5 
K56-66 MEC 16 µg/mL 4 µg/mL 0,5 0,5 
K56-69 WT 16 µg/mL 4 µg/mL 2 1 1 1 
K56-69 MEC 16 µg/mL 4 µg/mL 2 1 
K56-71 WT 16 µg/mL 4 µg/mL 1 0,75 1 1 
K56-71 MEC 16 µg/mL 4 µg/mL 1 0,75 
ATCC 16 µg/mL 4 µg/mL 1 0,5 or 0,75     























K56-5 WT 32 µg/mL 2 µg/mL 0,25 0,19 1 2 
K56-5 MEC 32 µg/mL 2 µg/mL 0,25 0,38 
K56-17 WT 32 µg/mL 2 µg/mL 0,5 0,38 0,5 0,5 
K56-17 MEC 32 µg/mL 2 µg/mL 0,25 0,19 
K56-18 WT 32 µg/mL 2 µg/mL 0,25 0,19 0,5 0,667 
K56-18 MEC 32 µg/mL 2 µg/mL 0,13 0,13 
K56-20 WT 32 µg/mL 2 µg/mL 0,25 0,38 1 0,658 
K56-20 MEC 32 µg/mL 2 µg/mL 0,25 0,25 
K56-23 WT 32 µg/mL 2 µg/mL 0,5 0,38 2 2 
K56-23 MEC 32 µg/mL 2 µg/mL 1 0,75 
K56-24 WT 32 µg/mL 2 µg/mL 0,25 0,25 1 0,752 
K56-24 MEC 32 µg/mL 2 µg/mL 0,25 0,188 
K56-31 WT 32 µg/mL 2 µg/mL 0,5 0,38 1 1 
K56-31 MEC 32 µg/mL 2 µg/mL 0,5 0,38 
K56-66 WT 32 µg/mL 2 µg/mL 1,0 0,38 0,5 1 
K56-66 MEC 32 µg/mL 2 µg/mL 0,5 0,38 
K56-69 WT 32 µg/mL 2 µg/mL 0,5 0,5 2 1,5 
K56-69 MEC 32 µg/mL 2 µg/mL 1,0 0,75 
K56-71 WT 32 µg/mL 2 µg/mL 0,25 0,375 1 1 
K56-71 MEC 32 µg/mL 2 µg/mL 0,25 0,375 
ATCC 32 µg/mL 2 µg/mL 0,5 0,38 or 0,5     






Appendix D: Clinical breakpoints for various antimicrobial agents regarding Enterobacteriaceae. The values are 
defined by EUCAST (93). 
 
Drug 
Enterobacteriacea acceptable limits of MIC (µg/mL) 
EUCAST MIC ATCC 25922 
Susceptible Resistant QC Limits K56-44 MEC 
Amoxicillin ≤8 >8 2-8 4-16 
Chloramphenicol ≤8 >8 2-8 1,5-6 
Ciprofloxacin ≤0,5 >1 0,004-0,016 0,012-0,048 
Gentamicin ≤2 >4 0,25-1 1,5-6 
Mecillinam ≤8 >8 0,03-0,25 16-64 
Nitrofurantoin ≤64 >64 4-16 6-24 
Tetracycline ≤4 ≥16 0,5-2 0,38-1,5 
Trimethoprim ≤2 >4 0,5-2 0,25-1 
 
	
 
 
